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ABSTRACT:

This dissertation is devoted to the study of the molecular biology of major tumor
suppressors, defined as those that prevent the cellular processes identified as the hallmarks of
cancer. Specifically, the major tumor suppressors pRb and STK11 are explored in the context of
osteosarcoma and lung cancer, respectively.
RB1 was the first tumor suppressor gene discovered. Over four decades of work have
revealed that the Rb protein (pRb) is a master regulator of biological pathways influencing
virtually every aspect of intrinsic cell fate including cell growth, cell-cycle checkpoints,
differentiation, senescence, self-renewal, replication, genomic stability and apoptosis. While
these many processes may account for a significant portion of RB1’s potency as a tumor
suppressor, a small, but growing stream of evidence suggests that RB1 also significantly
influences how a cell interacts with its environment, including cell-to-cell and cell-toextracellular matrix interactions. Chapter 2 highlights pRb’s role in the control of cell adhesion
and how alterations in the adhesive properties of tumor cells may drive the deadly process of
metastasis.
Chapter 3 defines a role for pRb as a suppressor of the progression to metastasis by
upregulating integrin α10. Transcription of this integrin subunit is herein found to be pRbdependent in mouse osteoblasts. Classic pRb partners in cell cycle control, E2F1 and E2F3, do
not repress transcription of integrin α10 and phosphorylation of pRb is not necessary for
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activation of the integrin α10 promoter. Promoter deletion revealed a pRb responsive region
between -108bp to -55bp upstream of the start of the site of transcription. pRb activation of
transcription also leads to increased levels of integrin α10 protein and a greater concentration of
the integrin α10 protein at the cell membrane of mouse osteoblasts. These higher levels of
integrin α10 correspond to increased binding to collagen substrate. Consistent with our findings
in mouse osteoblasts, we found that integrin α10 is significantly underexpressed in multiple solid
tumors that have frequent inactivation of the pRb pathway. Bioinformatically, we identified data
consistent with an 'integrin switch' that occurs in multiple solid tumors consisting of
underexpression of integrins α7, α8, and α10 with concurrent overexpression of integrin β4. pRb
promotes cell adhesion by inducing expression of integrins necessary for cell adhesion to a
substrate. We propose that pRb loss in solid tumors exacerbates aggressiveness by debilitating
cellular adhesion, which in turn facilitates tumor cell detachment and metastasis.
Lung cancer is the leading cause of cancer-related death in the U.S. and additional
targeted therapies are desperately needed to treat these patients. STK11 is the third most
frequently mutated gene in lung adenocarcinoma following only KRAS and TP53, yet its
mutational status is not currently clinically evaluated and no therapies have been approved to
specifically target its pathway. A deep understanding of the complex pathways controlled by
STK11 and their alterations in cancer are required to develop effective therapies for patients with
loss-of-function mutations. In Chapter 4 we present the current understanding of STK11,
focusing on its molecular biology and therapeutic implications, including a compilation of
studies evaluating STK11 somatic mutations in human lung cancer tissue and how the frequency
of these mutations varies across histological subtypes and patient populations. Finally, we
review the strategies being used to target STK11-deficient cancers at the clinical trial, pre-

vii

clinical, and basic science levels as well as proposing potential new therapies that might benefit
this patient population.
STK11 is a tumor-suppressor commonly mutated in lung adenocarcinoma (LuAd). There
are a number of agents that may selectively target the deregulated pathways in STK11 mutated
tumors, and thus, identifying the subset of adenocarcinomas that harbor these mutations could
have significant clinical benefit. In Chapter 5, we characterized a cohort of 442 adenocarcinoma
patients with respect to STK11 mutation status and subset of this cohort using immunochemistry,
gene expression, and western blotting. We found that measuring STK11 mutation status is
complicated by the fact that many STK11 mutations lead to expression of a stable protein that is
indistinguishable from wild type (WT) via immunohistochemistry. To circumvent this, we used
published cell line mutation and gene expression data to derive a signature correlating with
STK11 mutation status. This signature was validated in the cohort of 442 lung adenocarcinomas
and strongly correlates with mutation status (ROC curve AUC = 85.29). These data suggest that
STK11 mutation status may be best assessed by measuring the downstream targets included in
our signature.
.
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CHAPTER ONE:
Introduction to Major Tumor Suppressors

MAJOR TUMOR SUPPRESSORS AND THE HALLMARKS OF CANCER

Cancer is caused by catastrophic failure of numerous cellular processes. The progression
from normal cell to cancer cell is a multi-step process involving functional alterations in a series
of key regulatory proteins which can occur due to genetic mutations, alterations in gene
expression or due to the activity of infectious agents (e.g., human papilloma virus). Genes that
encode proteins that activate cell proliferation are often up-regulated in cancer via overexpression or by mutations that cause the resulting protein to be constitutively active. These
cancer promoting genes are called oncogenes. Their negative regulatory counterparts, genes that
encode proteins that prevent cancer from forming, are called tumor suppressors. Cancers grow
unchecked once these tumor suppressors are lost by mutation, hyper-phosphorylation, or
promoter methylation.
There have been more than 70 tumor suppressors identified to date1 of varying
importance. Some are lost late in tumorigenesis and are considered to be 'passenger mutations,'
those that confer little or no survival advantage to an existing cancer. Other tumor suppressors
are lost at the incipient stages of tumor neogenesis, this loss being crucial for the evolution from
normal cell to cancer cell. These 'driver mutations' occur in tumor suppressors that act as
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sentinels, each protecting the integrity of cellular processes crucial to maintaining a normally
functioning cell. These are the major tumor suppressors.
The processes that must occur in order for cancer to develop have been defined as a set of
eight 'hallmarks of cancer.' These processes include: sustaining proliferative signaling, evading
growth suppressors, activating invasion and metastasis, enable replicative immortality, inducing
angiogenesis, resisting cell death, and the two newest hallmarks: reprogramming energy
metabolism, and evading immune destruction.2 Each of these processes is protected by one or
more major tumor suppressors as outlined below.
'Sustaining proliferative signaling' is quintessentially what makes cancer such a deadly
disease. All of the other hallmarks support this unrestricted cellular proliferation in some way.
While this is a hallmark generally driven by oncogenes, a tumor suppressor that acts as a
guardian against uncontrolled growth is the phosphatase and tensin homolog (PTEN). PTEN
acts as a negative regulator of the AKT pathway serving to dephosphorylate PIP3 into PIP2,
thereby repressing AKT, signaling to the cell to stop dividing. Befitting of its status as a major
tumor suppressor, PTEN is also involved in regulation of apoptosis, migration, adhesion, and
genetic stability. It is commonly lost in many human cancers including 30-70% of prostate
cancer.3,4
'Evading growth suppressors' is driven by the loss of anti-proliferative signals. This is a
process guarded by the first tumor suppressor ever identified, pRb. pRb serves as a regulator of
the G1/S transition of cell cycle acting as a transcriptional repressor by binding E2F family
members at the promoter site of E2F-regulated genes. Mitogenic signaling activates the
formation of Cyclin D / CDK4/6 complexes which phosphorylate, and thus inactivate, pRb
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allowing for cell cycle progression. pRb has also been linked to numerous other cellular
processes and is lost or inactivated in the majority of human cancers.
'Activating invasion and metastasis' is the multi-step process by which epithelial cells
acquire the ability to invade adjacent tissues and eventually disseminate to distal sites setting up
distant metastases. This process begins with a series of steps known as the epithelial-tomesenchymal transition (EMT), controlled by the next major tumor suppressor, transforming
growth factor β (TGFβ). TGFβ acts as a tumor suppressor in the early stages of tumorigenesis,
serving to maintain a favorable cytokine and chemokine profile in the tumor microenvironment. 57

However, as the disease progresses, oncogenes can serve to convert TGFβ function to induce

EMT leading to increased invasion and migration. As such, TGFβ acts as both a major tumor
suppressor, and at advanced stages of disease, an oncogene.
'Enabling replicative immortality' occurs when cells are no longer limited to a finite
number of cell division cycles. In healthy cells, the progressive shortening of telomere repeat
sequences with each subsequent cell division causes cells to lose the ability to protect the ends of
the chromosomal DNA from forming end-to-end fusions. The sentinel of genomic integrity is
p53, which serves to assess DNA damage and activate DNA repair pathways as necessary, or if
the damage is beyond repair, induce apoptosis. TP53, which encodes for the p53 protein, is the
most frequently mutated gene in human tumors with over 25,000 mutations reported to dateI.
'Inducing angiogenesis' is the process by which tumors stimulate the growth of new blood
vessel vasculature in order to meet the increased metabolic demands of tumor tissues. The major
tumor suppressor that prevents this from happening is thrombospondin-1 (TSP-1). This inhibitor
of angiogenesis serves to limit vessel density by inhibiting chemotaxis toward pro-angiogenic
signals and inducing receptor-mediated apoptosis in activated endothelial cells. 8 It does this by
I
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binding transmembrane receptors displayed by endothelial cells and evoking suppressive signals
that counteract the proangiogenic stimuli. 9
'Resisting cell death' allows cancer cells to evade all of the aforementioned processes
whereby tumor suppressors activate apoptosis. Bax, Bak, and Bok are some of the pro-apoptotic
proteins responsible for triggering cell death through disrupting the mitochondrial membrane
resulting in release of cytochrome C. Apoptosis is a process activated and controlled by many of
the major tumor suppressors. Bax and Bak are transcriptional targets of p53, and Bok is
controlled by E2F, a member of the pRb pathway, in addition to acting as tumor suppressors in
their own right. These pro-apoptotic proteins are also suppressed in cancer when outnumbered
by the anti-apoptotic members of the Bcl-2 family (e.g., Mcl1) which directly bind and inactivate
their pro-apoptotic counterparts resulting in immortal cancer cells. Several studies have
measured these anti- and pro-apoptotic genes across a variety of cancers and found Bok to be
consistently deleted and Mcl1 to be amplified. 10
'Reprogramming energy metabolism' involves the counterintuitive switch in cancer cells
from oxidative phosphorylation to glycolysis even in the presence of oxygen. This phenomenon,
called the "Warburg effect," causes cancer cells to compensate for the reduced ATP production
of glycolysis in order to fuel their unrestricted growth. The major tumor suppressor that serves
to prevent dysregulated cellular energetics is STK11. It accomplishes this by suppressing cell
growth, angiogenesis, and bioenergetics under conditions of nutrient or oxygen stress11 through
its downstream effectors AMPK and mTOR. This is one of the two 'emerging hallmarks' and as
such, STK11 is one of the least characterized major tumor suppressors.
'Evading immune destruction' is the final hallmark and the second of the 'emerging
hallmarks.' It can be argued that the entire immune system acts as one of the body's most effect
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tumor suppressors serving to seek and destroy incipient neoplasias before they ever fully
develop. Constant immune surveillance routinely eliminates the vast majority of nascent tumors
that are highly immunogenic leaving behind weakly immunogenic clones to grow out and
develop into tumors. Evading detection by the immune system involves the immunosuppressive
branches of the immune system including regulatory T cells and myeloid-derived suppressor
cells and efforts to restore the immune response using cytokines, vaccines and antibody
immunotherapies (e.g., anti-CTLA4, anti-PD-1) have shown promise in certain patient subsets. 12
The remainder of this dissertation will focus on the major tumor suppressors pRb and
STK11 in the context of osteosarcoma and lung cancer, respectively.

OSTEOSARCOMA

Osteosarcoma is a type of cancer that develops in bone tissue. It primarily affects
children and young adults, likely linked to ages of rapid bone growth, but risk rises again in
adults over the age of 60, and is a disease that can occur at any age. There are thirteen types of
osteosarcoma that are divided into high-, intermediate-, and low-grade subtypes of varying
frequencies. When diagnosed at a localized stage, the 5-year survival rate is 60-80%II.
However, this drops to a survival rate of 15-30% when diagnosed with detectable metastases,
increasing to approximately 40% if the metastases are exclusively in the lungs or if the tumor,
including metastases, is completely resectableII. Osteosarcoma is more common in males than
females and slightly more common in African Americans than in whites. Children who have
hereditary retinoblastoma, marked by loss of the major tumor suppressor pRb, have an increased
risk of osteosarcoma later in life as it is also marked by a high frequency of pRb loss. Similarly,
II
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patients with Li-Fraumeni syndrome, characterized by the loss of the major tumor suppressor
p53, are also at an increased risk of developing osteosarcoma. Currently, the options to treat
osteosarcoma include surgery, chemotherapy, and in certain cases, radiation. First-line
chemotherapies include cisplatin, doxorubicin, high-dose methotrexate, ifosfamide, epirubicin,
or some combination of the above while second-line therapies for refractory or metastatic disease
include docetaxel, gemcitabine, cyclophosphamide, etoposide, topotecan, sorafenib, or some
combination thereofIII. Luckily, osteosarcoma is a relatively rare disease with only 5.5 boys and
4.5 girls out of every 1,000,000 aged 0-19 diagnosed in the U.S. between 2006-2010IV.
Unfortunately, this rarity also works against the patients with the disease as research funds are
channeled to more common diseases. It is our hope that our work in osteosarcoma will help lead
to more targeted and effective treatments in the future.

LUNG CANCER

In contrast to osteosarcoma, lung cancer is the second most diagnosed cancer in both men
and women following only prostate cancer and breast cancer, respectively and is the leading
cause of cancer-related death among both men and women, but similar to osteosarcoma, this
disease also suffers from a dearth of research funds. It is a disease inextricably linked to
smoking with risk increasing due to both quantity and duration of smoking. This perception of
lung cancer as a lifestyle disease has negatively impacted the research funds being directed
toward finding a cure for this deadly disease and ignores many of the other causes including
exposure to asbestos, radon, pollution, second-hand smoke, as well as other occupational
III
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hazards. Our work is focused on understanding the most predominant subtype, non-small cell
lung cancer (NSCLC) in order to provide benefit to the greatest number of people. NSCLC
accounts for approximately 85% of lung cancer diagnoses, with the remainder classified as small
cell lung cancer. NSCLC is further subdivided into histological subtypes: adenocarcinoma,
which accounts for approximately 35-40% all lung cancers, squamous cell carcinoma, which
accounts for 25-30% of all lung cancers, and large cell carcinoma which accounts 10-15% of all
lung cancersV. Most lung cancers are diagnosed in patients between 50-70 years old and is
slightly higher in males compared to females, and slightly higher in African-American men
compared to white men. The estimated 5-year survival for lung cancers diagnosed at a local
stage is 54%, however only 15% of lung cancers fall into this category. For all stages at
diagnosis combined, the 5-year survival rate is only 17% VI. Treatment decisions for lung cancer
have traditionally been based on histological subtype and stage of disease, however more
recently with the advent of targeted therapies, treatment decisions are being made based on a
patient's individual spectrum of mutations. One of the most common mutations in lung
adenocarcinoma is in the major tumor suppressor, STK11 and this relationship will be discussed
in detail later in the dissertation.

OVERVIEW OF THE DISSERTATION

In the following chapters I will describe my work on two major tumor suppressors: pRb
and STK11. Chapter 2 describes emerging work linking the tumor suppressor pRb to control
of cell adhesion and how alterations in this pathway may drive the process of metastasis.
V
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Chapter 3 presents the novel finding that the adhesion protein, integrin α10 is transcriptionally
activated by the tumor suppressor pRb using osteoblasts as a model system. It further elucidates
a signature consisting of changes in expression of four integrin subunits that occurs across
multiple solid tumor types. Chapter 4 presents an overview of what is known about the STK11
tumor suppressor, specifically focusing on its molecular biology and strategies to therapeutically
target STK11-deficient tumors. Chapter 5 describes a novel gene expression signature that can
be used to determine the mutational status of STK11 in lung adenocarcinoma patients and
clarifies why we believe this is the best option for a clinical diagnostic test. My conclusions and
future directions for research are outlined in Chapter 6, as well as describing the current
methods being explored to restore tumor suppressor function and my thoughts on the future of
cancer treatment.
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CHAPTER TWO:
The Retinoblastoma Protein: A Master Tumor Suppressor Acts as a Link Between Cell
Cycle and Cell Adhesion VII

ABSTRACT

RB1 was the first tumor suppressor gene discovered. Over four decades of work have
revealed that the Rb protein (pRb) is a master regulator of biological pathways influencing
virtually every aspect of intrinsic cell fate including cell growth, cell-cycle checkpoints,
differentiation, senescence, self-renewal, replication, genomic stability and apoptosis. While
these many processes may account for a significant portion of RB1’s potency as a tumor
suppressor, a small, but growing stream of evidence suggests that RB1 also significantly
influences how a cell interacts with its environment, including cell-to-cell and cell-toextracellular matrix interactions. This review will highlight pRb’s role in the control of cell
adhesion and how alterations in the adhesive properties of tumor cells may drive the deadly
process of metastasis.

VII

This chapter will be submitted for publication. See Appendix A for details.
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THE RETINOBLASTOMA PROTEIN (pRb): THE CLASSIC PARADIGM

Existence of the RB1 gene was predicted in 1971 from epidemiological evidence from
retinoblastoma families1 and the RB1 gene was identified over 15 years later.2 The initial
characterization of pRb function was guided by studies of DNA tumor viruses3,4 which pointed
to pRb's role as a regulator of the G1/S transition.5 It is now known that both the G1/S and G2/M
phases of the mammalian cell cycle are controlled by a complex and redundant molecular
pathway that involves members of the E2 promoter binding factor (E2F) 6, dimerization partner
(DP)7, pRb3, cyclin-dependent kinase (CDKs), Cyclins8, and CDK inhibitor(CDKN)9 families.
This pathway is disrupted in most, if not all, solid tumors. 10
While initial work on the function of pRb in cell cycle highlighted its role in the G 1/S
transition, work over the last three decades demonstrates that pRb controls most cellular
processes related to cell fate and DNA metabolism including cell-cycle checkpoints, tissue
differentiation and morphogenesis, senescence, self-renewal, replication, tissue-specific gene
expression, mitotic fidelity, genomic stability and apoptosis. 11-16. In this review we will refer to
these various cell intrinsic processes collectively as cell cycle. There are a number of
outstanding articles17-21 that review pRb’s role in the cell cycle processes and they will not be
repeated in detail here.
pRb’s activity is regulated by post-translational modifications, phosphorylation being the
most predominant.22 pRb phosphorylation by CDK4-Cyclin D and CDK2-Cyclin E induces Sphase entry.23,24 pRb is phosphorylated on at least 13 different serine/threonine residues
suggesting that specific patterns of pRb phosphorylation may represent a 'pRb code' in which
different pRb conformational variants mediate distinct protein-protein interactions. In non-

11

cancerous cells, anti-proliferative signals activate pRb by promoting its dephosphorylation by
serine and threonine type I phosphoprotein phosphatases and by inhibiting the Cyclin-CDK
complexes that phosphorylate pRb.25-27 This activation allows pRb to block progression to Sphase, promoting entry to G0 instead. A recent review has addressed the complexity of these
pRb kinases.22
pRb's strong tumor suppressive nature is evident in the fact that pRb function is lost in
most human cancers26,28,29, and also by the fact that oncogenic insults, such as Ras activation,
trigger a strong anti-oncogenic senescence program that depends on pRb. 11,30 Every component
of the pRb pathway that represses cell cycle is subject to mutational inactivation in some human
cancers and every component that induces cell cycle is subject to oncogenic up-regulation,
providing genetic evidence that the pathway as a whole is essential in tumor development.
CDKN proteins are subjected to inactivating mutations and epigenetic silencing. Cyclins, CDKs,
and rarely, E2Fs themselves are upregulated by translocations and gene amplifications. 31-34 The
rate of RB1 gene mutation varies significantly among different tumor types, but is highest in
retinoblastoma, osteosarcoma, and small cell lung cancer (SCLC). 28,35 Mutations targeting the
RB1 gene directly affect pRb function by either completely abrogating its expression or by
producing a non-functional protein.36 Other cancer types bearing wild type RB1 alleles still have
impaired pRb function due to alterations in genes coding for upstream pRb regulators. These
alterations range from inactivating mutations, deletions or epigenetic silencing of the p16 INK4A
locus (a CDKN family member), to alterations leading to Cyclin D or CDK4 overexpression. 32
The latter scenario results in pRb inactivation by chronic hyperphosphorylation. Therefore,
oncogenesis usually entails either a complete loss of pRb expression or its inactivation by
hyperphosphorylation.
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DEREGULATION OF ADHESION PROTEINS IN CANCER

Cadherins are calcium-dependent cell adhesion proteins that mediate cell-to-cell
adhesion. They are named for the tissue that they were first identified in (eg, E-cadherin, Ncadherin, and OB-cadherin were discovered in epithelial, neural, and osteoblast tissues,
respectively), but are not restricted exclusively to those tissues. Cadherins, together with
catenins, are the main components of adherens junctions, which are membrane protein
complexes that are stabilized by association with actin filaments densely packed under the cell
membrane.37 Their disruption is part of EMT during oncogenic progression and contributes to
metastasis by facilitating detachment of cancer cells from the primary tumor. 38 This disruption
consists of a 'cadherin switch' whereby expression of E-cadherin is repressed and N-cadherin is
upregulated.
Alterations in integrin expression have also been noted in cancers. Similar to the
'cadherin switch' occurring during EMT, an 'integrin switch' has been observed in multiple solid
tumors consisting of overexpression of integrin β4, and underexpression of integrins α7, α8, and
α10.39 Integrins are a family of 26 cell-to-extracellular matrix (ECM) adhesion receptor subunits.
Each functional integrin heterodimer consists of two type-1 (single membrane-spanning domain
with the C-terminus located cytoplasmically) transmembrane subunits, one α- and one β-subunit.
Integrins bind to multi-adhesive ECM components, organizing the cytoskeleton and activating
intracellular signaling pathways. They have been shown to affect cell shape, polarization,
cytoskeletal organization, cell motility, proliferation, survival, and differentiation. Integrins are
unusual among transmembrane receptors in that they signal bidirectionally, carrying both
mechanical and chemical signals. "Inside-out" signaling, known as "priming," is responsible for
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a conformational change in the integrin heterodimer which extends outward and induces
adhesiveness to the ECM. Adhesion is further strengthened by the lateral reorganization of
integrins into clusters, which may progress to dot-like focal complexes that mature into larger
focal adhesions and finally into streak-like fibrillar adhesions.40 The "integrin adhesome" is
comprised of 156 signaling, structural, and adaptor molecules that contribute to cytoskeletal
reorganization and catalytic activity as integrin tails have no catalytic activity of their own. 40
Integrin signaling, and the associated cross-talk with adjacent receptor tyrosine kinases, has been
linked to many pathways important in human cancer including the Ras/Raf/MEK/MAPK, PI3K/
PIP3/AKT, NF-κB, and pRb/E2F pathways.

NEW ROLES FOR pRb IN CELL ADHESION: REGULATION OF CADHERIN- AND
INTEGRIN-MEDIATED ADHESION

Cancer types showing high frequencies of mutational inactivation of the RB1 gene are
very aggressive relative to tumors with chronically hyperphosphorylated wild-type pRb. An
example is osteosarcoma, which at the time of diagnosis is consistently high grade and poorly
differentiated. These patients have a poor prognosis with 20%VIII of diagnosed cases already
having detectable metastases41 and only 10% achieving long-term disease free intervals.42
Osteosarcoma incidence is increased 1000 fold in patients who inherit RB1 mutations relative to
the general population,43 implicating pRb loss in osteosarcoma formation. pRb loss occurs in
over 70% of sporadic osteosarcomas, and loss of RB1 heterozygosity is present in 60-70% of
osteosarcomas and is indicative of a poor prognosis. 44

VIII

http://www.cancer.org/
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Like osteosarcoma, SCLC is characterized by a high rate (~90%) of mutational
inactivation of the RB1 locus.45 Patients with SCLC have a five-year survival rate of only 6%I,
which can increase to 54% if detected at a localized stage. Unfortunately, only 15% of SCLC
are detected at the localized stage. This extreme aggressiveness is in stark contrast to the fiveyear survival rates of tumors with lower rates of RB1 mutations such as breast, prostate, and
colorectal cancers when detected at a localized stage, which are 99%, 100%, and 90%,
respectively, according to the American Cancer Society Cancer Facts and Figures, 2014I.
Interestingly, lung cancer survival rate triples to 18% I in the non-small cell lung cancer (NSCLC)
subtype, which usually bears wild type RB1 alleles but instead exhibits preferential loss of the
p16INK4A locus with consequent pRb hyperphosphorylation. 46 The differences in survival rates
between SCLC and NSCLC suggest that increased aggressiveness may be associated more with
direct alterations of the RB1 locus than with chronic pRb hyperphosphorylation resulting from
alterations in other loci.
This RB1 effect is also observed in epithelial cancers. Although RB1 mutations are rare
in prostate cancer, a recent analysis of 50 castration-resistant prostate cancer patients47
demonstrated that patients with inactivating RB1 mutations have a 35 month reduction in median
overall survival relative to patients with WT RB1 (p=0.025). Specifically, the 16 patients with
RB1 mutations had a median overall survival of 70 months, versus 105 months in 34 patients
with WT RB1.
The data discussed above highlight the association between direct mutational targeting of
the RB1 gene and high mortality as demonstrated by the low 5-year survival rates of pRb-null
cancers. Given that metastases indicate aggressiveness and cause over 90% of cancer deaths, 48
we propose that pRb deficiency leads to a proclivity for early metastasis, that is, for early
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detachment of tumor cells from the primary tumor and invasion of adjacent and distal tissues. If
so, blocking cellular events associated with metastasis (eg, loss of cell polarity, epithelialmesenchymal transition (EMT), loss of cell adhesion) may be part of pRb´s tumor suppressive
arsenal. The first hints of a relation between pRb and metastasis came from studies published
over a decade ago implicating pRb in the stabilization of adherens junctions. Disruption of these
structures is part of EMT and contributes to metastases by facilitating detachment of cancer cells
from the primary tumor mass.38 Early studies showed that retinoblastomas, osteosarcomas, and
SCLC, known for their high frequencies of RB1 mutations, are composed of cells that lack stable
adherens junctions. In retinoblastoma, adherens junctions fail to anchor to the cortical actin
cytoskeleton.49 In osteosarcoma and SCLC, adherens junction proteins are downregulated and
aberrantly localized in the cytoplasm rather than at the cell membrane.50,51 Furthermore, a strong
correlation was found in retinoblastoma and osteosarcoma between abnormal adherens junctions
and invasive capacity,49,50 underscoring the notion that disruption of these structures is related to
invasion, and for the first time, implicating pRb loss in invasive behavior.
These early studies linking pRb to adherens junction integrity remained largely ignored
for years following their publication, possibly since they were mostly correlative and did not
establish a causal relationship between pRb loss and cell adhesion perturbations. An exception
was a study showing that pRb inactivation by SV40 large T antigen in MDCK epithelial cells
resulted in a mesenchymal conversion associated with invasiveness that could be reversed by
pRb re-activation.52 This study also offered the first mechanistic explanation of pRb's
involvement in cell adhesion by showing that pRb, together with the AP-2 transcription factor,
activated transcription of the E-cadherin promoter in epithelial cells.52 It took approximately a
decade for the next reports confirming the link between pRb and cell adhesion. These studies
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showed that pRb depletion disrupted cellular adhesion and induced a mesenchymal-like
phenotype. They further established that transcriptional regulation of E-cadherin expression by
pRb is a molecular link between pRb and cell adhesion. 53,54 Further implicating pRb loss in
EMT, pRb depletion results in up-regulation of several EMT-related transcriptional factors
including Slug and Zeb-1, which are known E-cadherin transcriptional repressors. 53,51
The studies described above strongly implicate pRb loss as a promoter of metastasis of
carcinomas, or epithelial tumors, specifically via the loss of epithelial markers such as Ecadherin and the acquisition of mesenchymal and migratory phenotypes. Additionally, it has
been shown that OB-cadherin, the predominant osteoblast cadherin, is also transcriptionally
regulated by pRb,55 implicating pRb loss in the molecular etiology of non-epithelial tumors such
as osteosarcomas. Conditional deletion of pRb in osteoblasts produces a 'cadherin switch' in
which OB-cadherin is replaced by N-cadherin,55 suggesting that pRb promotes the expression of
adhesion molecules characteristic of the fully differentiated state, regardless of cell type, while
repressing the expression of cell adhesion genes related to an undifferentiated phenotype. The
global nature of pRb's influence on cell adhesion was revealed by microarray analyses
comparing pRb-proficient versus pRb-deficient osteoblasts, which found that pRb affects the
expression of a variety of cell adhesion genes beyond cadherins and that cellular processes
related to cell adhesion are strongly affected by pRb. 55 Integrins were also found among the cell
adhesion genes whose expression is strongly affected by pRb, and cellular pathways involved in
integrin-mediated cell-to-ECM adhesion were also found to be under pRb control.55 In a followup study, it was shown that pRb induces transcription of integrin α10 in osteoblasts, regardless of
pRb phosphorylation status, with a corresponding increase in osteoblast binding to a collagen
substrate.39 This suggests that pRb mediates not only cadherin-dependent cell-to-cell adhesion,
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but also promotes integrin-dependent cell-to-ECM adhesion. Taken together, the studies
summarized above indicate a strong influence by pRb on cell adhesion that can either be
activating or repressive depending on the genes involved, up-regulating adhesion genes in
differentiated cells (eg, integrin α10) while down-regulating expression of adhesion genes
associated with invasiveness and metastasis (eg, N-cadherin).
pRb appears to regulate the formation of functional cell adhesive structures beyond
transcriptional regulation of cell adhesion genes, including facilitating the assembly of cell
adhesion gene products at the cell membrane. In the absence of pRb, the Rho GTPase Rac1 and
its effector the p21-activated protein kinase (Pak1) become up-regulated with consequent
phosphorylation of the Merlin tumor suppressor at Serine 518 by Pak1, which in turn causes
Merlin to detach from the cell membrane. 55 Therefore, pRb seems to promote adherens junction
assembly at the cell membrane by blocking the inactivating phosphorylation of Merlin by Pak1.
Merlin is a membrane-bound tumor suppressor and cytoskeleton adapter that stabilizes adherens
junctions by anchoring them to the cortical actin cytoskeleton under the plasma membrane. 56,57
Merlin loss, which is frequent in the human cancer syndrome Neurofibromatosis type 2 (NF2),
results in adherens junction disruption with consequent inactivation of contact-dependent growth
arrest.56 In summary, studies demonstrate that in the absence of functional pRb, transcription of
adherens junction components as well as their assembly at the cell membrane are both
compromised. This explains the observation that in pRb-deficient tumors, such as
retinoblastoma and osteosarcoma, not only do adherens junction proteins show diminished
expression, but they also fail to anchor to the cell membrane instead showing aberrant
cytoplasmic localization.49-51
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Invasiveness and metastases arise from a combination of loss of cell adhesion, onset of
migration facilitated by cytoskeletal reorganization and loss of cell polarity, and the capacity to
degrade basal laminae in order to escape the primary tumor site and penetrate adjacent tissues.
The data summarized above link pRb loss predominantly to perturbations in cell adhesion, but
pRb loss could exacerbate invasiveness by affecting other aspects of metastasis. For example,
pRb loss has been linked to increased expression of the matrix metalloproteinases (MMPs) that
remodel the ECM during cell invasion and metastasis. 58,59 MMP genes such as MMP9, MMP14,
and MMP15, which are usually over-expressed in NSCLC, have been shown to be regulated by
pRb.59 pRb reactivation was sufficient to inhibit MMP transcription, to reduce the invasion and
migration of cancer cells in vitro, and to reduce metastatic foci development in a tail vein lung
metastasis model in mice.59 pRb depletion also exacerbates the invasiveness of ErbB2-positive
breast cancer, suggesting that pRb loss may play a predominant role in the progression of in situ
breast ductal cell carcinoma to the invasive stages of the disease. 60
The data implicating pRb control of cell adhesion in cultured cells are abundant and
provide mechanistic insights that were lacking in early correlative studies. There are also data
providing insights into the consequences of pRb loss for in vivo tissue morphogenesis. When a
mouse model of osteosarcoma was generated by conditionally knocking out RB1 in osteoblasts,68
structural defects indicative of impaired osteoblast adhesion were observed in the calvaria of pRb
knockout mice. Specifically, pRb knockout mice lacked properly organized osteoblast layers
and showed osteoblasts that had migrated away from their proper position in the calvaria and
invaded the adjacent cartilage.68 pRb-deficient osteoblasts also expressed elevated levels of
Ezrin, a membrane-cytoskeleton linker and osteosarcoma metastasis marker. 55,61,62 Other mouse
models of osteosarcoma based on abrogation of pRb function have resulted in mice that develop
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fully penetrant, highly metastatic early onset osteosarcomas. 63 Given the importance of cell-tocell adhesion for osteoblast differentiation, pRb loss can be predicted to alter osteoblast
differentiation and lead to the formation of osteosarcoma. Osteoblasts originate from pluripotent
mesenchymal stem cells that differentiate into stroma, adipocytes, myoblasts, chrondroblasts,
fibroblasts, or osteoblasts.64,65 Stem cells committed to osteoblastic differentiation are sorted
from the rest of the mesenchymal precursors and align with, and adhere to, each other.
Homotypic, cadherin-based cell-to-cell interactions play a major role in sorting the pluripotent
stem cells into distinct lineages. Consistently, osteoprogenitor cells express a spatio-temporally
regulated repertoire of cadherins that provide cues for their alignment into a distinct
subpopulation within the bone marrow that will later differentiate into mature osteoblasts. 66,67
Adherens junction loss in pRb-null osteoblasts is accompanied by abnormal expression patterns
of the predominant osteoblast-specific cadherins OB- and N-cadherins, suggesting that the
timing of cadherin expression during osteoblast differentiation can be altered by pRb loss. 55 This
in turn suggests that pRb is required to ensure that expression of specific cadherins proceeds with
the right timing during differentiation, and that pRb loss could hamper proper homotypical
intercellular contacts, resulting in defective osteoblast differentiation with consequent disruption
of bone integrity and/or formation of bone tumors. Based on in vivo observations, it is plausible
that pRb is instrumental in the orchestration of cell proliferation and cell adhesion as part of
differentiation and bone morphogenesis. Disruption of which may be central to the molecular
etiology of osteosarcomas, which are characterized by poor differentiation and high frequencies
of RB1 mutations.
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A LINK BETWEEN CELL CYCLE CONTROL AND CELL ADHESION

In metastatic cancer cells, adhesion is aberrantly regulated by a variety of pathways
resulting in loss of cell-to-cell and cell-to-ECM contact and in dissemination of cancer cells
throughout the body. While more work is needed to elucidate those pathways, in many instances
this loss of adhesion has been tied to cell-cycle regulators, including members of the pRb-E2F
pathway.
Signaling from integrins through their downstream pathways occurs cooperatively
through crosstalk with growth factor receptors and has been linked to a variety of pathways
involved with cell cycle progression. Integrin-mediated cell-to-ECM adhesion acts as a
checkpoint for cell cycle entry. For example, in early work using pRb positive LNCaP and pRb
negative RU145 prostate epithelial cell lines, loss of β1 integrin contact to ECM inhibited G 1
CDK activity leading to an accumulation of hypophosphorylated pRb and subsequent Bcl-2
mediated apoptosis.68 More recently, Wang et al.69 found that overexpression of integrin α5 and
knockdown of integrin α6 decreased pulmonary metastasis of the highly invasive breast cancer
cell line 4T1 by inhibiting entry to S-phase through p27 upregulation, resulting in
downregulation of Cyclin E/CDK2 complexes. They also found that this modulation of integrin
expression upregulated E2F, which may then induce expression of Chk1 to regulate
cdc25A/Cyclin E/CDK2/pRb in a feedback loop. These findings implicate integrin α5 as a
metastasis suppressor and α6 as a metastasis promoter in breast cancer. For a comprehensive
review of how integrins control downstream entry to cell cycle progression see the review by
Moreno-Layseca and Streuli.70

21

Expression of E2Fs1-3 was shown to indirectly increase integrin β4 mRNA, protein, and
cell surface expression.71 These E2Fs were found to be downstream of active H-Ras in SUM159 breast carcinoma cells. Integrin α6β4 has been previously shown to enhance carcinoma
invasion, so the mechanism proposed by Yoon et al. 71 links active H-Ras, active E2Fs and
integrin α6β4 in a single pathway to promote invasion.
Long-term treatment of three NSCLC cell lines with recombinant CCN1 (Cysteine-rich
61), a secreted matrix-associated molecule, led to permanent cell cycle arrest in G 1. Addition of
CCN1 increased abundance of hypophosphorylated pRb and p53 and p21 accumulation. A
CCN1 mutant defective for binding integrin α6β1 and co-receptor heparan sulfate proteoglycans
was incapable of inducing senescence.72
The finding that pRb's effect on integrin expression is unaltered by its phosphorylation
state39 is particularly informative of the mechanisms linking pRb to cell adhesion and of the
coupling between cell cycle and cell adhesion. As discussed above, phosphorylation is a
mechanism of regulation of pRb function that abrogates pRb's capacity to bind and block E2F
transcription factors. The integrin α10 findings39 suggest that regulation of cell cycle
progression and cell adhesion by pRb may be mechanistically uncoupled since while pRb
hyperphosphorylation abrogates pRb's capacity to bind E2F and repress the cell cycle, it leaves
intact the capacity to induce integrin-mediated cell-to-ECM adhesion. This could shed some
light into the aggressive behavior of pRb-deficient tumors. The tendency of pRb-deficient
tumors to metastasize early in their development could be explained by the loss of both cell cycle
control and cell adhesion resulting from pRb loss. The residual pRb activity retained by tumors
with chronically hyperphosphorylated pRb, while not enough to halt initial tumor growth, may
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result in a less aggressive tumor and in deterring metastasis by helping to anchor the tumor
structure.
The data discussed above expand the paradigm of pRb function beyond cell cycle to
include roles in cell adhesion, and therefore implicate pRb loss in later stages of tumor
metastasis. Figure 2.1 shows a model depicting how pRb can integrate cell cycle control and
cell adhesion. These dual roles of pRb mechanistically explain how impairment of pRb function
contributes to the aggressive nature of some tumor types, expands pRb's arsenal of tumor
suppressive abilities, and explains the potency of this preeminent tumor suppressor more
adequately than the notion that pRb acts predominantly as a cell cycle repressor.

Figure 2.1: Model illustrating the function of pRb in cell cycle control and cell adhesion.
Pointed arrows indicate a stimulatory interaction. Blunt arrows indicate pathway repression.
Dotted lines represent indirect interaction or interactions via a mechanism that has not been fully
elucidated.
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TARGETING pRb LOSS AND ABERRANT ADHESION

The activity of the pRb kinases, the CDKs, is central to pRb pathway. For these reasons,
small molecule CDK inhibitors are being developed and examined in clinical trials for a number
of malignancies.73
Aberrant adhesion has been determinant of potential treatment options in several cancers.
For example, in erlotinib-resistant lung cancer cells harboring activating EGFR mutations, there
was increased expression of Src, integrins β1, α2, and α5 along with increased adhesion.
Silencing of integrin β1 restored erlotinib sensitivity. There was also increased expression of
integrins β1, α2, and/or α5 in refractory tumor samples from patients treated with erlotinib and/or
gefitinib.74
Furanodiene, a natural terpenoid derived from Rhizoma Curcumae, was found to have
anti-proliferative activity in 95-D human lung cancer cells when combined with paclitaxel.
These effects included down-regulation of protein levels of Cyclins D1 and B1, CDK6, and cMyc, as well as down-regulation of expression of integrin β4, focal adhesion kinase, and
paxillin.75 Previous studies had shown that combining furanodiene and paclitaxel had synergistic
anti-proliferative effects in NCI-H1299 and 95-D human lung cancer cell lines,76 and that
furanodiene decreased integrin β1 expression in breast cancer cells in a concentration-dependent
manner.77
Unsurprisingly, aberrant integrin signaling has been implicated in several human cancers
and specific therapies are being developed to target the integrin pathway including development
of anti-integrin α4 antibodies (eg, Natalizumab currently being evaluated in over 80 clinical
trials; http://clinicaltrials.gov), focal adhesion kinase (FAK) inhibitors (eg, GSK2256098
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currently being evaluated in three clinical trials; http://clinicaltrials.gov), integrin-linked kinase
(ILK) inhibitors, and RGD peptides (competitive inhibitors for the fibronectin-binding consensus
sequence such as eptifibatide and tirofiban). Unfortunately, integrins are also known mediators
of cell adhesion-mediated drug resistance (CAM-DR). Specifically, melanoma cells expressing
α4β1 and α5β1 integrins are resistant to doxorubicin and melphalan once bound to their
fibronectin ligands.78 This resistance is the result of cell cycle arrest in G 1 and is associated with
increased levels of the CDKN p27 and its inhibition of Cyclins A and E. 79
"Ligand-induced" adhesion, an integrin-mediated Rap-1-independent pathway that allows
unstimulated leukocytes to adhere to and migrate through exposed endothelial matrix or highdensity ligand, is CDK4-mediated, but pRb-independent. CDK inhibitors were able to block this
leukocyte adhesion and migration80.
The treatment options listed above are all designed to target either the pRb pathway or
the process of adhesion. With the new work being pioneered on the link between these two
pathways, it is our hope that either combining these drug classes, or developing new drugs to
specifically target this newly discovered link that treatment options will be more tailored to
individual cancers and increasingly effective in the future.

CONCLUSIONS: IMPLICATIONS FOR pRb AS A METASTASIS SUPPRESSOR

Recent work linking pRb to cell adhesion should reinvigorate the pRb field by
challenging the classic paradigm of pRb acting predominantly as a cell cycle regulator. New
information about pRb, as well as other oncogenes and tumor suppressors discovered decades
ago, continues to uncover novel effects and potentialities beyond cell cycle control.
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In the currently accepted model of tumor evolution, a step-wise accumulation of
mutations results in the progressive acquisition of aberrant cellular behaviors, each behavior
elicited by a particular mutation or sets of mutations. Mutations that inactivate tumor
suppressors like RB1 or that activate proto-oncogenes like KRAS would contribute to early stages
of tumor evolution by conferring a proliferative advantage to incipient tumor cells. These
mutations target cell cycle control by rendering cells capable of bypassing proliferative arrest,
contributing to unchecked tumor growth. However, a paradigm in which pRb acts
predominantly as a cell cycle repressor does not explain how pRb inactivation in early
tumorigenesis would contribute to later stages of metastasis, particularly to the detachment of
tumor cells from their original site and dispersion to distant tissues. The current model thus
mandates the acquisition of additional secondary mutations that confer metastasis potential at
later stages of tumor evolution. This multi-step model has been challenged, however, and
deemed conceptually inconsistent since the additional genetic hits that confer metastatic
capabilities at later stages of tumorigenesis do not necessarily exacerbate the proliferative
advantage conferred by the initial hits that disrupt cell cycle control. 81 In a tumor history that is
essentially a micro-evolutionary process, if secondary metastasis-related mutations do not further
enhance the previously acquired replicative advantage, the cells that acquired them will remain
rare within the tumor mass, outcompeted by more proliferative counterparts. Rather, it has been
suggested that mutations acquired by incipient tumor cells early in tumorigenesis confer not only
the replicative advantage that allows the initial tumor growth, but also later in tumorigenesis, the
proclivity to metastasize.81 Thus, the tendency to metastasize could be determined by mutant
alleles acquired early in tumor history. 81 This revised model predicts that fewer mutations are
required for a full-blown malignant phenotype if they target multifunctional genes such as RB1.
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Several lines of evidence support this. First, primary human breast cancers can shed malignant
cells into the bone marrow even when tumors are small and well-localized; second, DNA
microarray analyses reveal that metastatic tumor cells show gene expression profiles remarkably
similar to the cells contained in the primary tumor from which they were derived; third, certain
early gene-expression profiles in primary breast cancer tumors strongly predict metastasis and
can be detected before metastasis actually occurs. 81-86 A dual role for pRb in cell cycle and cell
adhesion is fully consistent with a model of metastases arising from fewer mutations. Thus, pRb
inactivation enhances proliferative capacity and growth of tumor mass during early
carcinogenesis, and also contributes to later stages of metastasis by promoting cell detachment
from the primary tumor. Further characterization of pRb's role in cell adhesion could contribute
to what has been described as "the hope to achieve an understanding of the complex process of
neoplastic transformation at the cellular level in terms of a small number of genetic changes." 87
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CHAPTER THREE:
Expression of Integrin alpha 10 is Transcriptionally Activated by pRb in Mouse
Osteoblasts and is Downregulated in Multiple Solid TumorsIX

ABSTRACT

pRb is known as a classic cell cycle regulator whose inactivation is an important initiator
of tumorigenesis. However, more recently it has also been linked to tumor progression. This
study defines a role for pRb as a suppressor of the progression to metastasis by upregulating
integrin α10. Transcription of this integrin subunit is herein found to be pRb-dependent in
mouse osteoblasts. Classic pRb partners in cell cycle control, E2F1 and E2F3, do not repress
transcription of integrin α10 and phosphorylation of pRb is not necessary for activation of the
integrin α10 promoter. Promoter deletion revealed a pRb responsive region between -108bp to 55bp upstream of the start of the site of transcription. pRb activation of transcription also leads
to increased levels of integrin α10 protein and a greater concentration of the integrin α10 protein
at the cell membrane of mouse osteoblasts. These higher levels of integrin α10 correspond to
increased binding to collagen substrate. Consistent with our findings in mouse osteoblasts, we
found that integrin α10 is significantly underexpressed in multiple solid tumors that have
frequent inactivation of the pRb pathway. Bioinformatically, we identified data consistent with

IX
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an 'integrin switch' that occurs in multiple solid tumors consisting of underexpression of integrins
α7, α8, and α10 with concurrent overexpression of integrin β4. pRb promotes cell adhesion by
inducing expression of integrins necessary for cell adhesion to a substrate. We propose that pRb
loss in solid tumors exacerbates aggressiveness by debilitating cellular adhesion, which in turn
facilitates tumor cell detachment and metastasis.

INTRODUCTION

The classic pRb pathway comprises pRb, the E2F family of transcription factors, cyclins
(primarily D type), cyclin-dependent kinases (CDKs; primarily 4 and 6), and two families of
CDK inhibitors (including p16Ink4a). In this classic view, pRb acts as a transcriptional repressor,
binding E2F family members at the promoter site of E2F-regulated genes and maintaining
transcriptional repression by blocking the transactivation function of E2F and by recruiting
additional factors that actively repress transcription. 1 Mitogenic signaling activates the formation
of cyclin/CDK complexes, which are responsible for phosphorylating, and thus inactivating,
pRb. Once hyperphosphorylated, pRb dissociates from E2F, which is now free to promote the
transcription of E2F-regulated genes.
In contrast to its negative regulatory control over E2F-mediated transcription, pRb has
also been found to positively regulate the expression of a number of genes. One such gene that
was discovered to be positively regulated by pRb is E-cadherin, a cell surface adhesion protein
that is a marker for epithelial cells. Both pRb and c-Myc activate transcription of E-cadherin in
epithelial cells in an AP-2 mediated manner.2 Similarly, pRb can bind members of the AP-1
family of transcription factors, including c-Jun, at its AP-1 consensus sequence resulting in
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stimulation of its transcriptional activity.3 Other genes known to be positively regulated by pRb
include the anti-apoptotic gene, Bcl-2, which is activated in an Ap-2 dependent manner4 and the
CDK inhibitor, p21, which is activated in an Sp1/Sp3 dependent manner 5. The transcription
factor Sp1 has also been found to be important in the upregulation of integrin α5 through
interaction with, and activation by, the transcription factor ZEB26.
pRb is inactivated either directly, through mutation of the Rb gene, or indirectly in the
majority of human cancers. Cancer types that have a greater than 90% frequency of pRb gene
mutation (e.g. retinoblastoma, osteosarcoma, small cell lung cancer) are also characterized by
disrupted cell-to-cell adhesion as mediated by adherens junctions. 7-9 Previous work has shown
that pRb-deficient osteoblasts do not undergo contact-dependent growth arrest, lack adherens
junctions, and exhibit altered cadherin expression. 10 This same work, via microarray, identified
a number of genes involved in cell-to-extracellular matrix (ECM) adhesion that may also be pRb
regulated. One such gene that was identified was integrin α10.
Integrins are a family of heterodimeric proteins made up of an α and a β subunit. They
mediate adhesion of cells to ECM ligands and are unique among transmembrane receptors in that
they have the ability to signal bidirectionally, carrying both mechanical and chemical signals. 11
Integrin α10 interacts exclusively with the β1 subunit to form α10β1 integrin. This is one of four
collagen-binding integrins and preferentially binds collagen type IV, the primary collagen type
of the basal lamina, but also binds collagens type VI and II, the primary collagen types of the
ECM of skeletal muscle and cartilage, respectively. 12 Integrin α10 is found primarily in
chondrocytes,13,14 but has also been found in chondrogenic mesenchymal stem cells, as well as
the endosteum (cell lining between bone marrow and bone) and periosteum (cell lining outside
the bone)15, areas rich in osteoblasts. In these regions, osteoblasts are responsible for bone
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development and produce osteoid, a matrix composed mainly of collagen type I. A constitutive
deletion of integrin α10 in mice resulted in a growth retardation of the long bones while
maintaining a normal lifespan and fertility.16
We hypothesized that not only was integrin α10 present in osteoblasts, but that it was
being regulated by pRb. In this article we demonstrate that pRb transcriptionally activates
integrin α10 and that the frequent loss of pRb in multiple solid tumors results in a dramatic
downregulation of integrin α10. pRb exerts its tumor suppressive effect primarily through
repressing cell proliferation and inducing a post-mitotic state as well as driving differentiation.
We would like to add 'maintaining cellular adhesion to the ECM' as a key tumor suppressive
function of pRb as we suspect that the subsequent downregulation of integrin α10 is part of a
greater 'integrin switch' that may have a vital role in the development of cancer metastasis. Our
study builds upon the growing literature that points to the loss of pRb as a key mediator of the
progression to metastasis.

MATERIALS AND METHODS

Cell lines and drug treatment
Cell lines and the mice they were derived from were previously described by Sosa-Garcia
et al.10 Briefly, primary osteoblasts were isolated and 3T3-immortalized from Rb1 conditional
knockout embryonic mice and their Rb wild-type littermates to produce pRb null and pRb wildtype MC3T3 cell lines, respectively. They were grown in Minimum Essential Medium Alpha
(MEM-α) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.
Approximately 2 x 106 MC3T3 Rb wild-type cells were cultured in p60 plates and received
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either a control treatment (complete media) or a drug treatment consisting of complete media
supplemented with either 200 nM or 500 nM of the CDK 4/6 specific inhibitor, PD0332991
(ChemiTek). Cells were harvested 48 h after treatment and underwent RNA extraction followed
by qRT-PCR as described below.

Plasmid vectors
The pGL3-p2717, Rb wt LP, Rb 7 LP18, pEGFPc2 (GenBank Accession #U57606),
pcDNA3-E2F119, pcDNA3-E2F320, CMV-Sp1(Plasmid 12097 purchased from
http://www.addgene.org), and pGL3-CIITA-Δ195 (Gift from Ken Wright, Moffitt Cancer
Center; Ghosh et al.21) have all been previously characterized. The novel promoter plasmids
were generated by PCR using the following primers: Δ590 forward (5'GAGAGGTACCTGTTGGGGGAAAGGTGCGGA-3'), Δ463 forward (5'GAGAGGTACCACAGGCAGTGACTCCCCAAAAGC-3'), Δ397 forward (5'GAGAGGTACCAGGTCACACAGTAGGACTGCCC-3'), Δ275 forward (5'GAGAGGTACCCCTACTTTCTGTTCCAAACTGGAGG-3'), Δ232 forward (5'GAGAGGTACCACCGTGCATAAAAGTAGCCTCAGAA-3'), Δ163 forward (5'GAGAGGTACCAGGGGGCAGCACCAAGGTAGAG-3'), Δ108 forward (5'GAGAGGTACCGGGCTCCCCACAGCTCCCTTC-3'), Δ55 forward (5'GAGAGGTACCTTAGCTGCCAGTGGGAGGGGG-3'), Reverse primer for all of the
aforementioned (5'-GAGAAGATCTAGACTCCATGGGCGCTTGTCC-3'). The products were
cleaved with KpnI and BglII and cloned into those sites of the pGL3-basic vector (Promega,
Chicago, IL, USA). Site-directed mutants were created using the Δ590 plasmid altered with the
following internal mutational primers and their reverse complements as reverse primers: Δ590-
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YY1 forward (5'-GTTATTTTGCATATCAACGGTTAAGATTAATAAG-3'), Δ590-HBP1(1)
forward (5'-TGGAGGAAATTATTGGGCGAATAAACCGTGCATA-3'), Δ590-PAX6 forward
(5'-TATTGAATAAATAAAATACGCATAAAAGTAGCCT-3'), Δ590-HBP1(2) forward (5'TTCCACCACCACTCCACGCCCATCCAACTTTATT-3'), Δ590-SP1 forward (5'GCTGCCAGTGGGAGGTTTAAGGATAGGAGGGAAA-3')

Luciferase assays
Approximately 100,000 cells per well of MC3T3 Rb null cells were cultured in 24-well
plates and transfected with a mixture containing 500 ng promoter construct, 50 ng Renilla
luciferase reporter (pRL-TK, Promega), and 2.5 μg of either Rb expression plasmid or empty
control vector (pEGFPc2) for an equal amount of DNA diluted in 100 μL serum free MEM-α for
each transfection. One microliter X-tremeGENE HP DNA transfection reagent (Roche
Disgnostics, Indianapolis, IN, USA) was added to the DNA mixture and allowed to incubate for
20 min before being added to the MC3T3 Rb null cells to a total volume of 600 μL (500 μL
serum free medium plus 100 μL transfection mixture). Cells were incubated with the
transfection mixture for 4 h before being returned to complete media (MEM-α plus 10% FBS,
1% penicillin/streptomycin). Cells were harvested 48 hours after transfection and luciferase
assays were performed using the dual-luciferase reporter assay system (Promega) following the
manufacturer's protocol and read using a 20/20n Luminometer (Turner Biosystems, Sunnyvale,
CA, USA) with standard promega protocol DLR-O-INJ. Experiments were done in triplicate.
To control for transfection efficiency, firefly luciferase values were normalized to the values for
Renilla luciferase.
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Quantitative real-time PCR
Total cell RNA was harvested using the RNeasy Mini Kit (Qiagen, Carol Stream, IL,
USA) following the manufacturer's instructions. Reverse transcription reactions were carried out
using iScript cDNA Synthesis Kit (Bio-Rad, Chicago, IL, USA). Real-time PCR was performed
using Bio-Rad iQ SYBR Green Supermix on a CFX96™ real-time PCR detection system (BioRad). The following primers were used: Itgα10 forward (5'-GGCTCCAACAGTATCTATCC3'), Itgα10 reverse (5'-TGCTCTCACAACTTCTTCC-3'), GAPDH forward (5'AACGACCCCTTCATTGAC-3'), GAPDH reverse (5'-CTCCACGACATACTCAGCAC-3')

Western blotting
Western blots were performed as previously described22. Briefly, cell lysates were
normalized for total protein content (35 μg) and subjected to SDS-PAGE. Detection of proteins
was accomplished using horseradish peroxidase-conjugated secondary antibodies and enhanced
chemiluminescence (ECL; Amersham Biosciences, GE Life Sciences, Pittsburgh, PA, USA).
Antibodies used include a mouse monoclonal antibody specific for endogenous pRb residues
701-928 (9309; Cell Signaling), a goat polyclonal antibody corresponding to amino acids 528546 of Sp1 (sc-59-G; Santa Cruz Biotechnology), and a mouse monoclonal β-actin antibody
(A5441; Sigma).

Immunofluorescence
Immunofluorescence was performed as previously described23 without permeabilization.
Briefly, cells were seeded in a Lab-Tak eight-chamber slide (Thermo Scientific, Waltham, MA,
USA) 1 day before experimentation. They were rinsed with PBS and fixed in 4%
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paraformaldehyde followed by neutralization with glycine. Cells were then sequentially
incubated in 10% bovine serum albumin (BSA), either anti-integrin α10 (AB6030; Millipore) or
anti-β-tubulin (2128S; Cell Signaling), followed by secondary AlexaFluor 488-conjugated goat
anti-rabbit antibody (Invitrogen, Life Technologies, Grand Island, NY, USA) with added DAPI.
This was followed by washing three times in PBS and covering the wells with Vectashield
mounting media (Vector Labs, Burlingame, CA, USA) and coverslips. Cells were imaged by the
Moffitt Cancer Center Microscopy Core with a Leica SP5, Chicago, IL, USA AOBS tandem
scanning inverted confocal microscope.

Functional adhesion assays
Functional adhesion assays were performed as previously described 24. Briefly, 96-well
Immunosorp (Nunc, Sigma Aldrich, St Louis, MO, USA) plates were coated with either 50 μL
(40 μg/mL) of soluble Cultrex mouse collagen IV (BD Biosciences, San Jose, CA, USA) or BSA
and allowed to evaporate overnight at room temperature. Cells were washed once in serum-free
MEM-α and resuspended at a density of 1 x 106 cells/mL with 1 x 105 cells added to each well.
After 2 h of adhesion, unattached cells were removed by three washes with MEM-α, and
adherent cells were fixed with 70% methanol for 10 min, dried, and subsequently stained with a
solution of 0.02% crystal violet at 0.2% ethanol. The stained cells were solubilized in 100 μL
Sorenson solution and absorbance was read at 540 nm with an automated 96-well plate reader
(VERSAmax, Sunnyvale, CA, USA). Mean and SE values were calculated from the results in
four independent wells. Experiments were repeated three times and results of representative
experiments are shown.
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Mining public databases
Microarray studies conducted on cancers included in the National Cancer Institute's list
of the 10 most common solid tumors (bladder, breast, colon and rectal, endometrial, kidney
(renal cell), lung, melanoma, pancreatic, prostate, thyroid;
http://www.cancer.gov/cancertopics/types/commoncancers) were analyzed using Oncomine
(http://www.oncomine.org, Compendia Bioscience, Ann Arbor, MI, USA). Data sets were
ordered by under- or overexpression: P-value of integrin analyzed. All known integrins with
corresponding probesets were analyzed including integrins α1-11, α2B, αL, αM, αX, αV, αE, β18, and βL1. The only integrins found to be significantly under- or overexpressed in at least five
of the seven data sets were integrins α7, α8, α10, and β4. These four integrins were further
analyzed using seven previously published microarray studies25-31 to evaluate their mRNA
expression. Six studies used Affymetrix human genome arrays with the probe set 216331_at for
integrin α7, 214265_at for integrin α8, 206766_at for integrin α10, and 204990_s for integrin β4
with the exception of the Kaiser study which used probe set 211905_at for integrin β4. The
seventh study by Haqq et al. used a microarray of 20,862 cDNA targets representing 19,740
unique genes (Research Genetics, Huntsville, AL, USA) with the probe set H44722 for integrin
α10, and R87964 for integrin α8. The study by Dyrskjot et al. 32 included nine samples of normal
bladder and five samples of normal bladder mucosa as well as 28 samples of superficial bladder
cancer (superficial transitional cell carcinoma) comprising 15 tumor biopsies without
surrounding carcinoma in situ and 13 tumor biopsies with surrounding carcinoma in situ. The
study by Haqq et al.26 included three samples of normal skin and six samples of melanoma. The
study by Hou et al.27 included 65 samples of normal lung and 27 samples of squamous cell lung
carcinoma. The study by Jones et al. 28 included 23 samples of normal kidney and eight samples
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of renal pelvis urothelial carcinoma (transitional cell cancers of the renal pelvis). The study by
Kaiser et al.29 included five samples of normal colon and 13 samples of colon mucinous
adenocarcinoma. The study by Landi et al. 30 included 49 samples of normal lung and 58 samples
of lung adenocarcinoma. The study by Richardson et al. 31 included seven samples of normal
breast and 40 samples of ductal breast carcinoma.

Statistical methods
A data set of non-small cell lung cancer (NSCLC) tumor and adjacent normal samples
(GSE19188), was used to identify genes differentially expressed between tumor and adjacent
normal. Sample GSM475805 was identified as a corrupt CEL file and excluded from all
analyses. Data were normalized with the RMA algorithm using the libaffy software 33, and
principle component analysis (PCA) was performed on the remaining 155 samples, using the
Evince software (UmBio AB, Umeå, Sweden), to identify outliers. Three tumor samples
(GSM475677, GSM475706, GSM475780) clustered in the middle of the adjacent normal
samples, and one adjacent normal sample (GSM475666) fell within the tumor distribution.
These samples were discarded for all further tumor versus adjacent normal analysis. An
additional six outlier adjacent normal samples (GSM475752, GSM475755, GSM475766,
GSM475781, GSM475807, GSM475811) were identified as falling outside the otherwise tight
adjacent normal distribution, lying between the adjacent normal and tumor clusters. Subsequent
analyses (data not shown) confirmed that these samples exhibit a more tumor-like gene
expression profile than the other adjacent normals, and were thus discarded from further tumor
versus adjacent normal analysis. The final tumor plus adjacent normal data set, after discarding
outliers, consisted of 58 adjacent normal and 87 tumor samples. Samples were then ranked by
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their respective scores from the first principle component of a partial least squares discriminate
analysis (PLS-DA) model, trained on tumor versus adjacent normal, to order them from most
normal-like to most tumor-like global gene expression.
Statistical significance of data was calculated using a two-tailed Student's t-test in
Microsoft Excel.

RESULTS

Integrin α10 expression is pRb-dependent in mouse osteoblasts
In previous work we examined the effects of pRb deficiency in mouse osteoblasts and
identified a role for pRb as a regulator of cell adhesion10. The microarray screen conducted as
part of that work identified integrin α10 as a potential pRb-activated gene. Integrin α10
expression in osteoblasts has not been previously measured, but is known to be high in
chondrocytes. Both osteoblasts and chondrocytes are derived from a common progenitor cell so
as a first step, we measured the endogenous expression levels of integrin α10 mRNA in mouse
osteoblast MC3T3 cells, both wild-type and pRb null, at two different levels of confluency to
verify that these cells are integrin α10 positive and that integrin α10 is indeed a pRb target
(Figure 3.1). We found that integrin α10 expression is much higher in pRb wild-type cells as
compared with their pRb null counterparts. Expression levels were also found to be highest at
100% confluency likely due to increased ECM availability at higher cell densities. The high
levels of endogenous integrin α10 and the obvious changes in wild-type versus pRb null cells
make MC3T3 mouse osteoblast cells an ideal model system to study changes in integrin function
and expression engendered by pRb.
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Figure 3.1 Expression of endogenous integrin α10 mRNA in MC3T3 wild-type and MC3T3
pRb null cells. RNA extraction was performed at two different levels of cell confluency
followed by qRT-PCR with integrin α10 specific primers to determine expression levels relative
to GAPDH. The MC3T3 pRb null expression levels were set as one for each RNA extraction.
Asterisk represents significant p-value: *=p<0.05.
Phosphorylation of pRb is not necessary for activation of integrin α10 promoter
We hypothesized that pRb was regulating integrin α10 at the level of transcription. In
order to test this, we defined a putative integrin α10 promoter as the 590 base pairs of DNA
immediately upstream of the start of the site of transcription using the fully sequenced
chromosome 3 from the Mouse Genome Project (NCBI Reference Sequence: NC_000069.6). A
variety of constructs were made of this integrin α10 putative promoter (Figure 3.2) and were
determined to be active. When acting as a regulator of cell cycle progression, the
phosphorylation status of pRb determines whether or not cells proceed through the G1
checkpoint. Upon phosphorylation by cyclin D/CDK4/6 complexes, pRb becomes inactivated
and allows progression to S-phase. To determine if phosphorylation status altered the role of
pRb in regulating expression of integrin α10, and to narrow down the minimal responsive region
of the integrin α10 promoter, three deletion constructs of the integrin α10 promoter were
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transfected into MC3T3 cells along with the wild-type pRb large pocket or the nonphosphorylatable pRb large pocket (Figure 3.3A). Phosphorylation was not necessary for the
activation of the integrin α10 promoter. In order to confirm that differences in activation were
due to intrinsic properties of the pRb constructs and not due to increased transfection efficiency
of either one, a western blot was conducted and the constructs expressed comparable levels of
protein (Figure 3.3B). As a final confirmation that the phosphorylation of pRb is not necessary
for upregulation of integrin α10 MC3T3 pRb wild-type cells were treated with two doses of
PD0332991, a drug specific for CDKs 4 and 6, the two CDKs responsible for phosphorylating
pRb (Figure 3.3C). Endogenous levels of integrin α10 mRNA were measured 48 h after
application of the drug. Cells treated with the drug did not exhibit any inhibition of integrin α10
mRNA expression as compared with the untreated control cells.

E2F1 and E2F3 do not repress transcription of integrin α10
One of the best characterized roles of pRb is as a regulator of transcription involving its
interaction with the E2F family of transcription factors. E2F involvement would likely be the
result of the E2F transcription factor repressing transcription of the integrin α10 promoter.
Addition of pRb would activate the integrin α10 promoter through alleviating this E2F-mediated
repression. Previous studies have identified E2F1 as a repressor of the Mcl-1 promoter19. We
explored the potential of E2F1 and E2F3 to repress the integrin α10 promoter in the absence of
pRb. The addition of E2F1 and E2F3 expression plasmids did not result in repressed
transcription (Figure 3.4) suggesting that pRb is acting through a non-E2F mediated pathway.
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Figure 3.2 Schematic of the integrin α10 promoter. (A) Schematic shows the eight 5’-nested
deletion constructs characterized (Δ590, Δ463, Δ397, Δ275, Δ232, Δ163, Δ108, Δ55), the five
site-directed mutants of the Δ590 construct (Δ590-YY1, Δ590-HBP1(1), Δ590-PAX6, Δ590HBP1(2), Δ590-SP1) with their 4 base pair substitutions, the putative transcription factor binding
sites (underlined), and the primers used for cloning (highlighted in gray). All constructs begin at
the base pair by which they are named (upstream relative to the start of the site of transcription)
and end at +60.
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Figure 3.3 Effect of pRb phosphorylation status on integrin α10 transcription. (A) Three
integrin α10 promoter deletion constructs (Δ590, Δ463, Δ163) and a p27 promoter construct
control were co-transfected separately with either pEGFPc2 (control), pRb wild-type large
pocket (Rb wt LP), or pRb non-phosphorylatable large pocket (Rb 7 LP) into MC3T3 pRb null
cells. Promoter activation was measured by luciferase activity. p27 control activity is set to one.
(B) Western blot of control (pEGFPc2), pRb wild-type large pocket (Rb wt LP), and pRb nonphosphorylatable large pocket (Rb 7 LP) transfected into MC3T3 pRb null cells. Blot was
probed for pRb (9309; Cell Signaling) and β-Actin (A5441; Sigma). (C) Expression of
endogenous integrin α10 mRNA in MC3T3 wild-type cells treated with the CDK 4/6 specific
drug, PD0332991 at two different doses (200nM and 500nM). RNA extraction was performed
48 hours post drug treatment followed by qRT-PCR with integrin α10 specific primers to
determine expression levels relative to GAPDH. The untreated MC3T3 pRb wild-type
expression levels were set as one. Asterisks represent significant p-values as follows: *=p<0.05,
**=p<0.01, and ***=p<0.001.
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Figure 3.4 Effect of E2F1 and E2F3 on Integrin α10 promoter activation. Three integrin
α10 promoter deletion constructs (Δ590, Δ463, Δ163) and a p27 promoter construct control were
co-transfected separately with either pEGFPc2 (control), E2F1pcDNA3 (E2F1), or
E2F3pcDNA3 (E2F3) into MC3T3 pRb null cells. Promoter activation was measured by
luciferase activity. p27 control activity is set to one. No changes were statistically significant.

Exploring the possible involvement of other transcription factors
According to the Biological General Repository for Interaction Data sets (BioGRID;
http://www.thebiogrid.org),34 human pRb associates with 145 unique interactors. Bioinformatic
analysis of the integrin α10 promoter was conducted to look for putative binding sites for these
145 interactors using the Genomatix program MatInspector (Genomatix Software GmbH,
Munich; http://www.genomatix.de; Cartharius et al.35 and Quandt et al.36). This analysis
revealed putative transcription factor binding sites for known pRb interacting transcription
factors YY1, yin-yang 1, from -321 to -301bp, HBP1, high-mobility group box transcription
factor 1, from -248 to -224bp (HBP1(1)), PAX6, paired box homeotic gene-6, from -241 to
-223, a second HBP1 site from -88 to -64bp (HBP1(2)), and Sp1, specificity protein 1, from -42
to -26bp (Figure 3.2). We decided to further analyze the potential involvement of Sp1 as it is
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not only known to interact with pRb, but has previously been shown to have a role in the
upregulation of integrin α5 along with ZEB26. Additionally, this site identified on the mouse
promoter was also conserved on the human promoter with a putative binding site of base pairs
-17 to -1 with respect to the start of the site of transcription (data not shown). We explored the
possibility that Sp1 could act with pRb as a co-activator of transcription of the integrin α10 gene.
Sp1 was added in the presence and absence of pRb to three integrin α10 promoter constructs in
MC3T3 pRb null cells looking for a synergistic activation when both Sp1 and pRb were added,
however no activation was observed to correspond with the addition of Sp1 (data not shown).
As there was no evidence of Sp1 having a role in the activation of integrin α10, we
decided to look at the other putative pRb interacting transcription factor binding sites on the
integrin α10 promoter. Site-directed mutants were made in which the four base pairs most critical
for the binding of the transcription factor to the promoter (the 'canonical binding site' as
determined by Genomatix) were mutated (Δ590-YY1, Δ590-HBP1(1), Δ590-PAX6, Δ590HPB1(2), and Δ590-Sp1). In addition to the site-directed mutants, a series of progressive
deletion mutants were made in which each successive deletion removed one of the putative
transcription factor binding sites (Δ397, Δ275, Δ232, Δ108, and Δ55). The site-directed
mutation of individual binding domains did not reveal a single motif responsible for pRb
activation of the integrin α10 promoter (Figure 3.5B) pointing to either a lack of individual
importance of these transcription factors in the activation of the integrin α10 promoter, or
continued binding despite the mutated base pairs suggesting that they were not, in fact, the
canonical binding site. Interestingly, the progressive deletions of the integrin α10 promoter
resulted in progressively diminished transcriptional activation, all the while not losing the
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activating effect of pRb up until the Δ55 construct suggesting a pRb responsive region between
-108bp to -55bp upstream of the start of the site of transcription (Figure 3.5C).
As all of the constructs and controls are activated by the addition of pRb, a control
experiment was conducted using the promoter of CIITA, the class II major histocompatibility
complex transactivator, a gene not known to be pRb regulated. As expected, the addition of pRb
did not cause any significant change in CIITA transcription (Figure 3.5A).
We used a bioinfomatic approach to create the list of transcription factors that were
potentially involved in activating integrin α10, but relying on the computer algorithm and
exploring only the region directly upstream of the start of the site of transcription may have
excluded a key transcription factor. A different starting point could have been a literature search,
or including a greater region of the upstream sequence to search. With this list in mind,
additional experiments that could have been conducted to determine the involvement of other
transcription factors include using siRNA to deplete the transcription factors to see if any
significant decrease in integrin α10 activation occurred. Conversely, only Sp1 DNA was added
into the luciferase experiments to see if it activated the expression of integrin α10, but other
transcription factor DNAs could also have been added. An EMSA could have been used to
determine if any of these transcription factors bind to the promoter sequence of integrin α10.
Although not shown in any figures, multiple ChIP experiments were conducted to observe pRb
binding along the integrin α10 promoter. These same samples could have immunoprecipitated
using antibodies directed against the putative transcription factors involved to show their binding
to the integrin α10 promoter. This binding could be in complex with pRb, a possibility that
could be explored using co-immunoprecipitation to determine if the transcription factors were
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directly bound to pRb. Additional mutagenesis experiments could have been used to confirm the
specific promoter regions necessary for activation by these transcription factors.

pRb wild-type osteoblasts exhibit higher protein levels and adhesion of Integrin α10
compared with matched pRb null cells
pRb-activated expression of integrin α10 mRNA is effectively translated into higher
levels of integrin α10 protein as visualized by immunofluorescence (Figure 3.6A). Integrin α10
protein in pRb wild-type osteoblasts is located in high concentrations at the cell membrane
forming a well-defined cellular margin. The matched pRb-null osteoblasts are characterized by
lower levels of membranous integrin α10 protein with irregular signal at cell margins. For both
cell types nuclear staining with the integrin α10 antibody is likely nonspecific. No differences in
β-tubulin staining levels and patterns were observed between the two cell lines.
Next, we decided to test the functionality of the integrin α10 protein in both the pRb
wild-type and pRb null osteoblasts. As expected, the higher levels of integrin α10 protein in pRb
wild-type osteoblasts directly corresponded to a statistically significant change of approximately
47% greater binding to collagen IV as compared with matched pRb null cells (Figure 3.6B).
This indicates that not only is more integrin α10 protein present in pRb wild-type osteoblasts, but
this protein is functional and maintains cellular adhesion to ECM substrate that is lost when pRb
is no longer present.
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Figure 3.5 Effect of pRb on activation of site-directed and deletion mutants of the integrin
α10 promoter. (A) A CIITA promoter construct and a p27 promoter construct control were cotransfected separately with either pEGFPc2 (control) or pRb wild-type large pocket (Rb wt LP)
into MC3T3 pRb null cells. Promoter activation was measured by luciferase activity. p27
control activity is set to one. (B) An integrin α10 promoter construct (Δ590), five site-directed
mutants of that construct (Δ590-YY1, Δ590-HBP1(1), Δ590-PAX6, Δ590-HBP1(2), Δ590-SP1)
and a p27 promoter construct control were co-transfected separately with either pEGFPc2
(control) or pRb wild-type large pocket (Rb wt LP) into MC3T3 pRb null cells. Promoter
activation was measured by luciferase activity. p27 control activity is set to one. (C) Six
integrin α10 promoter deletion constructs (Δ590, Δ397, Δ275, Δ232, Δ163, Δ55) and a p27
promoter construct control were co-transfected separately with either pEGFPc2 (control) or pRb
wild-type large pocket (Rb wt LP) into MC3T3 pRb null cells. Promoter activation was
measured by luciferase activity. p27 control activity is set to one. Asterisks represent significant
p-values as follows: *=p<0.05, **=p<0.01, and ***=p<0.001.
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Figure 3.6 Effect of pRb on Integrin α10 protein levels and function. (A) MC3T3 pRb wildtype and pRb null cells were probed with antibodies against β-tubulin (2128S; Cell Signaling)
and integrin α10 (AB6030; Millipore) (green) and stained with DAPI (blue; nuclei). They were
then examined using confocal immunofluorescence microscopy. Representative images are
shown. (B) MC3T3 pRb wild-type and pRb null cells were incubated with either collagen IV or
BSA substrate and allowed to adhere. Attached cells were permeabilized and stained with
crystal violet. Absorbance at 540nm was measured. Asterisk represents significant p-value:
*=p<0.05.
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Identification of an 'integrin switch' that occurs in multiple solid tumors
Analysis of integrin expression in public databases of the most common solid tumors led
to the identification of a four integrin signature that appears as consistently significant changes in
mRNA expression levels between tumors and their matched normal tissues. Specifically, the
signature consists of overexpression of integrin β4 and underexpression of integrins α7, α8, and
α10 (Table 3.1, Figure 3.7A-D). Increased expression of integrin β4 has also previously been
linked to metastasis in human osteosarcoma cells. 37
Due to the relative rarity of osteosarcoma and the propensity to treat the disease before
tumor resection, no data on integrin α10 expression in tumor and matched normal tissue could be
obtained. Instead, seven solid tumor types from the National Cancer Institute's list of the ten
most common solid tumors were examined, including two types of lung cancer, and all exhibited
significantly underexpressed integrin α10 as compared to their matched normal control tissues
(Table 3.1, Figure 3.7E-H). Specifically, ductal breast carcinoma, the most common type of
breast cancer, had the largest fold-change31 (Figure 3.7G) followed by melanoma26 (Figure
3.7H). Squamous cell lung carcinoma, a subtype of non-small cell lung cancer (85% of all lung
cancers) which accounts for 25-30% of all non-small cell lung cancers, had the third highest
fold-change27 (Figure 3.7F). Next was superficial bladder cancer, which accounts for 80% of
bladder cancers32. Renal pelvis urothelial carcinoma was next 28; this study also showed
downregulation or no change in renal pelvis urothelial cancer in all of the adhesion genes
analyzed (e.g. ADAM12, ADAMTS5, ADAM9, TNFAIP6, GNRH2, CD47, CD36, ICAM1,
CD96, CD99, SCARB1, CDW52). Sixth was lung adenocarcinoma, which accounts for roughly
50% of all non-small cell lung cancers30 (Figure 3.7E). Finally, colon mucinous
adenocarcinoma was seventh.29
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Table 3.1 Integrin expression in seven common solid tumor types.
Database
Dyrskjot Bladder 3
Haqq Melanoma
Hou Lung
Jones Renal
Kaiser Colon
Landi Lung
Richardson Breast

Integrin α7
Fold
p-value
Change
-1.587
1.63E-05
NC
2.68E-01
-1.734
1.64E-14
-1.523
2.45E-05
NC
9.40E-02
-1.239
1.01E-07
-5.362
3.41E-06

Integrin α8
Fold
p-value
Change
-1.475
2.25E-04
-1.504
3.00E-03
-5.742
1.91E-15
-3.993
7.00E-17
-1.494
1.00E-03
-2.375
4.58E-17
NC
1.70E-02

Integrin α10
Fold
p-value
Change
-1.604
3.99E-07
-3.471
2.04E-04
-1.828
2.88E-18
-1.499
5.91E-10
-1.222
6.09E-06
-1.357
9.02E-14
-3.491
2.00E-06

Integrin β4
Fold
p-value
Change
2.313
1.82E-05
N/A
N/A
3.591
8.92E-10
2.500
2.00E-03
2.852
5.81E-05
1.588
3.36E-07
-2.735*
1.86E-08

Data comes from OncomineTM (www.oncomine.org, Compendia Bioscience, Ann Arbor, MI).
The fold change value is determined by comparing the means of the two classes in an analysis on
a log2 scale and then converting that difference to a linear scale (www.oncomine.org). NC = no
significant difference in expression between normal and tumor tissue. N/A = this study did not
have a probe for the gene of interest. Only one significant change occurred in the opposite
direction of the other six datasets and is denoted with an asterisk.

CONCLUSIONS

In this study we have demonstrated that integrin α10 is expressed in mouse osteoblasts
and that the expression of this gene is activated at a transcriptional level by pRb. This activation
of expression directly leads to increased integrin α10 protein levels and greater adhesion to a
collagen substrate. Our analysis of publically available databases revealed that integrin α10 is
significantly downregulated in tumor tissue compared with normal in multiple solid tumors.
These findings point to an important role for changes in integrin α10 expression during disease
progression.
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Figure 3.7 Changes in integrin expression occur in multiple solid tumors. (A-D) The
GSE19188 dataset of NSCLC tumor and adjacent normal samples was ranked from most normal
to most tumor-like. Samples 1-58 are the adjacent normals (black diamonds) while samples 59145 represent tumor samples (light gray diamonds). Gene expression was determined via
microarray for integrin α7 using probe 216331_at (A), α8 using probe 214265_at (B), α10 using
probe 206766_at (C), and β4 using probe 204990_s_at (D). (E-H) Oncomine™
(www.oncomine.org, Compendia Bioscience, Ann Arbor, MI) was used for analysis and
visualization of integrin α10 expression in four common solid tumor types. Datasets were
ordered by under-expression: P-value of Itga10. (E) Analysis of integrin α10 expression in
normal lung (n=49) vs. lung adenocarcinoma (n=58) from the Landi Lung database. (F)
Analysis of integrin α10 expression in normal lung (n=65) vs. squamous cell lung carcinoma
(n=27) from the Hou Lung database. (G) Analysis of integrin α10 expression in normal breast
(n=7) vs. ductal breast carcinoma (n=40) from the Richardson Breast 2 database. (H) Analysis
of integrin α10 expression in normal skin (n=3) vs. melanoma (n=6) from the Haqq Melanoma
database.
The downregulation of integrin α10 following pRb loss may be part of a larger oncogenic
event in which cellular differentiation is lost. Differentiation has previously been measured as
part of a 'cadherin switch' in which epithelial cells lose their epithelial phenotype and become
more mesenchymal in character. We propose that there is a simultaneous 'integrin switch'
involving the downregulation of integrins α10, α7, α8, and potentially other positive prognostic
integrins with concurrent upregulation of less favorable integrins, including integrin β4, that
results in a loss of adhesion to the local extracellular matrix allowing previously anchored cells
to metastasize. As a highly tissue specific integrin, loss of α10 may be associated with a loss of
differentiation. There is potential to use integrin α10 levels as a prognostic marker. High levels
indicate a tumor that has retained differentiation and will likely have better overall survival while
decreased expression levels are an indicator of a more advanced disease state in which pRb has
been lost or mutated.
This study builds upon our previous work defining a role for pRb as a regulator of mouse
osteoblast cell adhesion10 and adds to the growing literature that links pRb to the metastatic
cascade.39
61

REFERENCES

1.

Knudsen ES, Wang JYJ. Targeting the RB-pathway in Cancer Therapy. Clinical Cancer
Research. Feb 2010;16(4):1094-1099.

2.

Batsche E, Muchardt C, Behrens J, Hurst HC, Cremisi C. RB and c-Myc activate
expression of the E-cadherin gene in epithelial cells through interaction with transcription
factor AP-2. Mol. Cell. Biol. Jul 1998;18(7):3647-3658.

3.

Nead MA, Baglia LA, Antinore MJ, Ludlow JW, McCance DJ. Rb binds c-Jun and
activates transcription. Embo Journal. Apr 1998;17(8):2342-2352.

4.

Decary S, Decesse JT, Ogryzko V, Reed JC, Naguibneva I, Harel-Bellan A, Cremisi CE.
The retinoblastoma protein binds the promoter of the survival gene bcl-2 and regulates its
transcription in epithelial cells through transcription factor AP-2. Mol. Cell. Biol. Nov
2002;22(22):7877-7888.

5.

Decesse JT, Medjkane S, Datto MB, Cremisi CE. RB regulates transcription of the
p21/WAF1/CIP1 gene. Oncogene. Feb 2001;20(8):962-971.

6.

Nam EH, Lee Y, Park YK, Lee JW, Kim S. ZEB2 upregulates integrin alpha 5 expression
through cooperation with Sp1 to induce invasion during epithelial-mesenchymal
transition of human cancer cells. Carcinogenesis. Mar 2012;33(3):563-571.

7.

Van Aken EH, Papeleu P, De Potter P, Bruyneel E, Philippe J, Seregard S, Kvanta A, De
Laey JJ, Mareel MM. Structure and function of the N-cadherin/catenin complex in
retinoblastoma. Invest. Ophthalmol. Vis. Sci. Mar 2002;43(3):595-602.

8.

Kashima T, Kawaguchi J, Takeshita S, Kuroda M, Takanashi M, Horiuchi H, Imamura T,
Ishikawa Y, Ishida T, Mori S, Machinami R, Kudo A. Anomalous cadherin expression in
osteosarcoma - Possible relationships to metastasis and morphogenesis. American
Journal of Pathology. Nov 1999;155(5):1549-1555.

9.

Rodriguez-Salas N, Palacios J, de Castro J, Moreno G, Gonzalez-Baron M, Gamallo C.
Beta-catenin expression pattern in small cell lung cancer: correlation with clinical and
evolutive features. Histology and Histopathology. Apr 2001;16(2):353-358.

62

10.

Sosa-Garcia B, Gunduz V, Vazquez-Rivera V, Cress WD, Wright G, Bian H, Hinds PW,
Santiago-Cardona PG. A Role for the Retinoblastoma Protein As a Regulator of Mouse
Osteoblast Cell Adhesion: Implications for Osteogenesis and Osteosarcoma Formation.
Plos One. Nov 2010;5(11).

11.

Guo WJ, Giancotti FG. Integrin signalling during tumour progression. Nature Reviews
Molecular Cell Biology. Oct 2004;5(10):816-826.

12.

Barczyk M, Carracedo S, Gullberg D. Integrins. Cell and Tissue Research. Jan
2010;339(1):269-280.

13.

Camper L, Hellman U, Lundgren-Akerlund E. Isolation, cloning, and sequence analysis
of the integrin subunit alpha10, a beta1-associated collagen binding integrin expressed on
chondrocytes. The Journal of biological chemistry. Aug 7 1998;273(32):20383-20389.

14.

Camper L, Holmvall K, Wangnerud C, Aszodi A, Lundgren-Akerlund E. Distribution of
the collagen-binding integrin alpha10beta1 during mouse development. Cell Tissue Res.
Oct 2001;306(1):107-116.

15.

Varas L, Ohlsson LB, Honeth G, Olsson A, Bengtsson T, Wiberg C, Bockermann R,
Jarnum S, Richter J, Pennington D, Johnstone B, Lundgren-Akerlund E, Kjellman C.
Alpha10 integrin expression is up-regulated on fibroblast growth factor-2-treated
mesenchymal stem cells with improved chondrogenic differentiation potential. Stem cells
and development. Dec 2007;16(6):965-978.

16.

Bengtsson T, Aszodi A, Nicolae C, Hunziker EB, Lundgren-Akerlund E, Fassler R. Loss
of alpha10beta1 integrin expression leads to moderate dysfunction of growth plate
chondrocytes. J Cell Sci. Mar 1 2005;118(Pt 5):929-936.

17.

Wang CG, Hou XH, Mohapatra S, Ma YH, Cress WD, Pledger WJ, Chen JD. Activation
of p27(Kip1) expression by E2F1 - A negative feedback mechanism. Journal of
Biological Chemistry. Apr 1 2005;280(13):12339-12343.

18.

Knudsen ES, Wang JY. Dual mechanisms for the inhibition of E2F binding to RB by
cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol. Oct
1997;17(10):5771-5783.

19.

Croxton R, Ma Y, Cress WD. Differences in DNA binding properties between E2F1 and
E2F4 specify repression of the Mcl-1 promoter. Oncogene. Feb 28 2002;21(10):15631570.
63

20.

He Y, Armanious MK, Thomas MJ, Cress WD. Identification of E2F-3B, an alternative
form of E2F-3 lacking a conserved N-terminal region. Oncogene. Jul 13
2000;19(30):3422-3433.

21.

Ghosh N, Gyory I, Wright G, Wood J, Wright KL. Positive regulatory domain I binding
factor 1 silences class II transactivator expression in multiple myeloma cells. The Journal
of biological chemistry. May 4 2001;276(18):15264-15268.

22.

Flores AM, Kassatly RF, Cress WD. E2F-3 accumulation is regulated by polypeptide
stability. Oncogene. Mar 12 1998;16(10):1289-1298.

23.

Chen L, Chen DT, Kurtyka C, Rawal B, Fulp WJ, Haura EB, Cress WD. Tripartite motif
containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F
interactions. The Journal of biological chemistry. Nov 23 2012;287(48):40106-40118.

24.

Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS.
Reduction in drug-induced DNA double-strand breaks associated with beta1 integrinmediated adhesion correlates with drug resistance in U937 cells. Blood. Sep 15
2001;98(6):1897-1903.

25.

Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, Orntoft TF.
Gene expression in the urinary bladder: A common carcinoma in situ gene expression
signature exists disregarding histopathological classification. Cancer Research. Jun 1
2004;64(11):4040-4048.

26.

Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S,
Miller JR, Allen RE, Singer MI, Leong SPL, Ljung BM, Sagebiel RW, Kashani-Sabet M.
The gene expression signatures of melanoma progression. Proceedings of the National
Academy of Sciences of the United States of America. Apr 26 2005;102(17):6092-6097.

27.

Hou J, Aerts J, den Hamer B, van IJcken W, den Bakker M, Riegman P, van der Leest C,
van der Spek P, Foekens JA, Hoogsteden HC, Grosveld F, Philipsen S. Gene ExpressionBased Classification of Non-Small Cell Lung Carcinomas and Survival Prediction. Plos
One. Apr 22 2010;5(4).

28.

Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu XS, Joseph
M, Pantuck AJ, Jonas D, Libermann TA. Gene signatures of progression and metastasis
in renal cell cancer. Clinical Cancer Research. Aug 15 2005;11(16):5730-5739.

64

29.

Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ, Freudenberg J, Chen
XD, Haigis K, Jegga AG, Kong S, Sakthivel B, Xu H, Reichling T, Azhar M, Boivin GP,
Roberts RB, Bissahoyo AC, Gonzales F, Bloom GC, Eschrich S, Carter SL, Aronow JE,
Kleimeyer J, Kleimeyer M, Ramaswamy V, Settle SH, Boone B, Levy S, Graff JM,
Doetschman T, Groden J, Dove WF, Threadgill DW, Yeatman TJ, Coffey RJ, Aronow
BJ. Transcriptional recapitulation and subversion of embryonic colon development by
mouse colon tumor models and human colon cancer. Genome Biol. 2007;8(7).

30.

Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE,
Fukuoka J, Hames M, Bergen AW, Murphy SE, Yang P, Pesatori AC, Consonni D,
Bertazzi PA, Wacholder S, Shih JH, Caporaso NE, Jen J. Gene Expression Signature of
Cigarette Smoking and Its Role in Lung Adenocarcinoma Development and Survival.
Plos One. Feb 20 2008;3(2).

31.

Richardson AL, Wang ZGC, De Nicolo A, Lu X, Brown M, Miron A, Liao XD, Iglehart
JD, Livingston DM, Ganesan S. X chromosomal abnormalities in basal-like human breast
cancer. Cancer Cell. Feb 2006;9(2):121-132.

32.

Knudsen ES, Knudsen KE. Retinoblastoma tumor suppressor: where cancer meets the
cell cycle. Experimental biology and medicine. Jul 2006;231(7):1271-1281.

33.

Eschrich SA, Hoerter AM. Libaffy: software for processing Affymetrix GeneChip data.
Bioinformatics. Jun 15 2007;23(12):1562-1564.

34.

Stark C, Breitkreutz BJ, Chatr-Aryamontri A, Boucher L, Oughtred R, Livstone MS,
Nixon J, Van Auken K, Wang X, Shi X, Reguly T, Rust JM, Winter A, Dolinski K, Tyers
M. The BioGRID Interaction Database: 2011 update. Nucleic acids research. Jan
2011;39(Database issue):D698-704.

35.

Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M,
Bayerlein M, Werner T. Matlnspector and beyond: promoter analysis based on
transcription factor binding sites. Bioinformatics. Jul 1 2005;21(13):2933-2942.

36.

Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new
fast and versatile tools for detection of consensus matches in nucleotide sequence data.
Nucleic acids research. Dec 11 1995;23(23):4878-4884.

37.

Wan X, Kim SY, Guenther LM, Mendoza A, Briggs J, Yeung C, Currier D, Zhang H,
Mackall C, Li WJ, Tuan RS, Deyrup AT, Khanna C, Helman L. Beta4 integrin promotes
osteosarcoma metastasis and interacts with ezrin. Oncogene. Sep 24 2009;28(38):34013411.
65

38.

Sellers WR, Novitch BG, Miyake S, Heith A, Otterson GA, Kaye FJ, Lassar AB, Kaelin
WG, Jr. Stable binding to E2F is not required for the retinoblastoma protein to activate
transcription, promote differentiation, and suppress tumor cell growth. Genes Dev. Jan 1
1998;12(1):95-106.

39.

Johnson JL, Pillai S, Pernazza D, Sebti SM, Lawrence NJ, Chellappan SP. Regulation of
Matrix Metalloproteinase Genes by E2F Transcription Factors: Rb–Raf-1 Interaction as a
Novel Target for Metastatic Disease. Cancer Research. January 15, 2012
2012;72(2):516-526.

66

CHAPTER FOUR:
The Molecular Biology and Therapeutic Implications of STK11/LKB1 Mutations in Lung
CancerX

ABSTRACT

Lung cancer is the leading cause of cancer-related death in the U.S. and additional
targeted therapies are desperately needed to treat these patients. STK11 is the third most
frequently mutated gene in lung adenocarcinoma following only KRAS and TP53, yet its
mutational status is not currently clinically evaluated and no therapies have been approved to
specifically target its pathway. A deep understanding of the complex pathways controlled by
STK11 and their alterations in cancer are required to develop effective therapies for patients with
loss-of-function mutations. In this article we present the current understanding of STK11,
focusing on its molecular biology and therapeutic implications, including a compilation of
studies evaluating STK11 somatic mutations in human lung cancer tissue and how the frequency
of these mutations varies across histological subtypes and patient populations. Finally, we
review the strategies being used to target STK11-deficient cancers at the clinical trial, preclinical, and basic science levels as well as proposing potential new therapies that might benefit
this patient population.
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OVERVIEW

In the U.S., lung cancer is the second most diagnosed cancer in both men and women
following only prostate cancer and breast cancer, respectively.1 Although the incidence rate has
been declining in men over the past two decades, in women the incidence rate has just recently
started to decrease. Lung cancer is the leading cause of cancer-related death among both men
and women. Non-small-cell lung cancer (NSCLC) represents more than 80% of lung cancer
diagnoses and has an overall 5-year survival rate of approximately 16%, which decreases
precipitously among patients diagnosed with late stage disease. 2
Traditionally, decisions on lung cancer treatment have been based on clinical
characteristics such as stage at diagnosis, performance status of the patient, and tumor histology.
More recently, however, treatment strategies involve the subdivision of NSCLC into molecular
subsets based on gain-of-function mutations in oncogenes and loss-of-function mutations in
tumor suppressors. Many of these alterations occur disproportionately across lung tumor
histopathologies,3-5 which likely indicate differences in carcinogenesis and cell type of origin.
Mutations in these genes confer an advantage to tumor cells by activating signaling pathways
crucial for cancer cell proliferation and survival. Loss-of-function mutations in tumor suppressor
genes are more common events than gain-of-function mutations in oncogenes, but have
traditionally been much more difficult to treat therapeutically as restoring their function would
involve delivery of wild type DNA to tumor cells and no viable delivery systems have been
developed to date. Instead, the most effective therapies are small molecule inhibitors that block
gain-of-function activity, especially of proteins on the cell membrane. Drugs designed to
specifically inhibit these molecular targets have significantly extended survival times for NSCLC
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patients whose tumors harbor these gain-of-function mutations.6 Restoring the function of
mutated tumor suppressors is generally achieved through targeting key downstream signaling
pathways that exhibit increased activity when the tumor suppressor is lost. Development of
therapeutic regimes to replace the activity of tumor suppressors requires a deep understanding of
the far-reaching effects of their loss-of-function mutations and studying the molecular biology of
these key proteins is central to this strategy. STK11 is one of these key tumor suppressors.
The STK11 gene encodes a tumor suppressor located on chromosome 19p13.3 that
encodes the serine/threonine protein kinase also known as liver kinase β1 (LKB1). The gene
spans 23kb and is made up of nine coding exons (exons 1-9) and a final non-coding exon (exon
10). Germline mutations in STK11 were first identified in patients with Peutz-Jeghers
syndrome,7 a rare autosomal dominant disorder which is associated with an increased risk of
gastrointestinal and other malignancies, 8,9 with over 80% of patients developing cancer by the
age of 70.10 Studies have also found that STK11 somatic mutations are quite common in
NSCLC, especially among adenocarcinomas, suggesting an important role for STK11 in lung
tumorigenesis.11-18 In this article we review the current evidence regarding the role of STK11
mutations in lung cancer focusing on the molecular biology and therapeutic implications.

STUDIES OF STK11 MUTATIONS IN HUMAN LUNG CANCER

Although rarely mutated in most human cancers, STK11 is the third most frequently
mutated gene in lung adenocarcinoma after KRAS and TP53.5,11,15,16,19 Table 4.1 summarizes
studies that have generated STK11 somatic mutation data from human lung cancer tissue. The
collection of these data from primary tumor samples is often complicated by the fact that tumor
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suppressor genes such as STK11 can undergo mutational and deletional events that can be missed
due to normal tissue contamination, resulting in marked underrepresentation. With that in mind,
the frequency of STK11 mutations in these studies range from 0.6% to 44.4%. Two studies
reported the frequency of STK11 mutations across adenocarcinoma subtypes,5,20 some analyzed
the overall frequency of STK11 mutations across multiple histological subtypes,21-25 while other
studies reported STK11 inactivating mutations in other lung cancer histology subtypes (e.g., 19%
of squamous cell carcinomas, 14% of large cell carcinomas, and 25% of adenosquamous
carcinomas).14-16,21,26,27 The spectrum of mutation frequency across histological subtypes is
consistent with previously published data from mouse models where STK11 deficiency altered
the resulting spectrum of tumor histology. 12 Specifically, STK11-deficient tumors were found in
adenocarcinoma, squamous, and large cell carcinoma, whereas the tumors in other genetic
models of murine lung cancer were solely adenocarcinoma histology.12 None of the studies
found any associations with overall survival which contrasts what is known about EGFR and
KRAS mutations. EGFR mutations are associated with sensitivity to EGFR-tyrosine kinase
inhibitors, namely gefitinib and erlotinib, 28 but it is also known that patients with EGFR mutant
tumors have better overall survival regardless of treatment, 29 while lung cancer patients with
KRAS mutant tumors are associated with worse overall survival, especially in patients with
adenocarcinoma and early stage disease.30 However, STK11 inactivation has been shown to be a
prominent biomarker for poor outcome in cervical cancer, with a median survival of only 13
months for patients with STK11-deficient tumors versus greater than 100 months for wildtype
tumors.26
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Table 4.1: Studies reporting STK11 somatic mutations in human lung cancer.
REFERENCE

Avizienyte et
al.31

HISTOLOGY

STAGE

GENDER

N= ≥1 STK11
MUTATIONS
(%)
1 Adenocar.
(12%)

ASSOCIATIONS

SSCP
analysis

NR

NR

Manual
sequencing
Manual
sequencing

NR

NR

6 (30%)

NR

Stage I only,
Stage I-III,
Mets

NR

1 (0.9%)
3 (12.5%)
3 (12%)

81 Adenocarcinoma,
14 Squamous cell,
1 Adenosquamous,
2 Large cell carcinoma,
1 Small cell carcinoma,
1 Carcinoid
80 Adenocarcinoma,
42 Squamous cell,
5 Adenosquamous,
10 Large cell carcinoma,
6 Unknown
105 Adenocarcinoma,
54 Squamous cell

Manual
sequencing

57 Stage I,
13 Stage II,
27 Stage III,
3 Stage IV

59 Males,
41 Females

3 (3%)

STK11 mutation
only men/smokers;
No EGFR/ STK11
double mutants
All 3 patients with
STK11 mutations
were male smokers

Direct exon
sequencing
and copy
loss by
MLPA
Direct
sequencing

NR

NR

37 (26%)

NR

108 Males,
51 Females

1 (0.6%)

Wilkerson et
al.20
Gill et al.25

Adenocarcinoma

Direct
sequencing
Direct
sequencing

82 Stage I,
77 Stage IIIV
NR

NR

9 (12.3%)

79 Males,
45 Females

7/62 (11.4%)*

Okuda et al.34

Adenocarcinoma

Direct
sequencing

157 Males,
17 Females

5 (2.9%)**

Koivunen et
al.21

207 Adenocarcinoma,
92 Squamous cell,
9 Adenosquamous

Direct
sequencing

187 Males,
187 Females

34 (11%)

Strazisar et al.22

51 Adenocarcinoma,
67 Squamous cell,
11 Large cell carcinoma
206 Adenocarcinoma,
24 Large cell carcinoma

DHPLC
mutation
screening
Sequenom
LungCarta
panel
cDNA
sequencing

78 Stage I,
47 Stage IIIV
105 Stage I,
24 Stage II,
38 Stage III,
7 Stage IV
188 Stage I,
59 Stage II,
47 Stage III,
8 Stage IV
NR

824delC in male
smoker with
adenocarcinoma
No association
with survival
6 mutants were
Adenocarcinoma;
1 was Squamous
No mutations
among light
smoker males.

107 Males,
22 Females

3 (2.3%)

NR

158 Males,
72 Females

13 (5.7%)

31 Stage I,
8 Stage II,
5 Stage III,
1 Stage IV
143 Stage I,
72 Stage II,
135 Stage III,
174 Stage IV
NR

16 Males,
29 Females

20 (44.4%)

361 Males,
163 Females

8/101 (7.9%)

No association
with overall
survival

54 Males,
43 Females
NR

14 (14.4%)

78 Males,
121 Females

28 (11%)

3 EGFR/STK11
double mutants
Neg. correlation
between EGFR
and STK11
mutations
Mutations in
EGFR and STK11
mutually exclusive

SanchezCespedes et al.11
Matsumoto et
al.15
Onozato et al.32

Ji et al.16

Lee et al.33

Tan et al.24

12 Squamous cell,
3 Large cell carcinoma,
1 Small cell carcinoma,
12 Adenocarcinoma
Adenocarcinoma

ASSAY

106 Adenocarcinoma,
24 Adenocarcinoma,
25 Brain metastases

68 Adenocarcinoma,
49 Squamous cell

Tam et al.35

Adenocarcinoma

An et al.23

354 Adenocarcinoma,
144 Squamous cell,
26 Large cell carcinoma

Direct
sequencing

Suzuki et al.36

Adenocarcinoma

Ding et al.5

Adenocarcinoma

Direct
sequencing
Direct
sequencing

Chitale et al.37

Adenocarcinoma

Sequenombased
mutation
screens

75 Stage I,
91 Stage II,
8 Stage III,
10 Stage IV
135 Stage I,
27 Stage II,
36 Stage III,
2 Stage IV

34 (18%)

NR

No association
with survival;
Caucasians and
smokers more mut.
All 3 mutations
were in
Adenocarcinoma
No association
with overall
survival
NR

NR=not reported *Sequenced 8 coding exons in 62 of 124 tumors that had loss of heterozygosity
and identified eleven tumors (11.3% overall) with STK11 mutation. **Only exons 1, 6, and 7.
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Similar to mutations in KRAS and EGFR, there is evidence to suggest ethnic/racial
differences in STK11 mutations. Studies in Asian populations including Japanese, Korean, and
Chinese have reported much lower STK11 mutation rates, ranging from 3-7% in lung
adenocarcinoma, compared to Whites.21,32,38,39 This observation is similar to KRAS mutations in
lung cancer, which frequency co-occur with STK11 mutations, where it has been noted that lung
tumors in Western populations harbor a higher frequency of KRAS mutation (15-50%) compared
to Asian populations (5-15%). Asian populations have been found to express an STK11 germline
F354L polymorphism at a higher frequency than Western populations which has been reported in
10% of Chinese38 and 6% of Korean populations compared to 0.2% of a Finnish population.40
This allele has not been associated with cancer predisposition, and is likely a polymorphism that
has no effect in lung cancer, but has been previously reported to affect cell polarity maintenance
in an AMPK-dependent manner.41
The STK11 kinase domain spans over 60% of the entire length of the protein,
encompassing amino acids 49-309 of the total 433. Mutations have been found throughout the
entire gene without any well characterized hotspots. In general, recurrent C-terminal mutations
located outside of the kinase domain do not impair STK11 kinase activity or interfere with its
ability to promote growth arrest. These mutations do, however, impair STK11's regulation of the
AMP-activated protein kinase (AMPK) cascade and cell polarity. These mutations include
P324L, F354L (described above to have an increased frequency in Asian popluations), and
T367M.41
The STK11 protein is catalytically active as a heterotrimeric complex with the STE20related adaptor protein α (STRADα) and mouse protein-25 (MO25) and mutations have been
found to interfere with STK11's interaction with these binding partners. An investigation of 34
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point mutations in STK11 revealed that 12 of these mutants failed to interact with these STRADα
and MO25.42 An analysis of the mutation sites led to the discovery of two binding sites on
opposite surfaces of MO25 required for assembly of the heterotrimeric complex. 42
Variations in STK11 single nucleotide polymorphisms (SNPs) have also been linked to
various diseases including gene variants in STK11 rs8111699 which contribute to differences in
insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess,
leading to the conclusion that the girls with the least favorable endocrine-metabolic profile
improved the most with metformin therapy. 43 Another study that analyzed 772 patients with
surgically resected colorectal adenocarcinoma for the STK11 rs741765 SNP found that the GG
genotype was significantly associated with a worse disease free survival and overall survival. 44

DOWNSTREAM TARGETS OF STK11

As mentioned above, STK11 is catalytically active as part of a heterotrimeric complex.
After translation, the nuclear localized STK11 binds STRADα, which shuttles the complex to the
cytoplasm.45 STRADα is also responsible for stimulating STK11 catalytic activity through an
allosteric mechanism involving binding STK11 as a pseudosubstrate.46 This interaction between
STRADα/STK11 is further stabilized by MO25, which interacts with STK11's activation loop. 46
An additional STK11 complex was discovered in which an STK11 isoform that differs in
the C-terminal region, but not one that lacks a portion of the kinase N-terminal lobe domain, was
found to interact with the chaperones Hsp90 and Cdc37. 47 This non-canonical
STK11/Hsp90/Cdc37 complex is catalytically inactive unlike the STK11/STRADα/MO25
complex. Dissociation of the STK11/Hsp90 complex triggers recruitment of both Hsp/Hsc70
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and CHIP proteins which are responsible for activating STK11 degradation. They proposed that
these two chaperone complexes with antagonizing activities are responsible for fine tuning the
cellular levels of STK11 protein. 47
STK11 is a multi-functional kinase and has been found to be involved in a broad
spectrum of cellular activity including metabolism, polarity, epithelial-mesenchymal transition,
cell cycle regulation, apoptosis, and autophagy. 14 Many of these functions are regulated through
STK11 activation of the AMPK cascade, 48 which is achieved through STK11 directly
phosphorylating T172 on AMPK.49 Identification of an STK11 splice variant that is lacking
S431, but is able to activate AMPK equally as effective as full-length STK11, led to the
conclusion that phosphorylation of STK11 at S431 is not required for downstream
phosphorylation of AMPK and other kinases, as has been previously suggested. 50 Activation of
AMPK and other members of the AMPK family is crucial to STK11's role as a regulator of
cellular energy metabolism and cell polarity. 49,51 AMPK in particular has been found to have
great importance as it acts as a tumor suppressor, serving to promote p53 acetylation and
subsequent apoptosis of hepatocellular carcinoma cells. 52
Downstream of STK11, AMPK activation negatively regulates the mTOR pathway.
AMPK directly phosphorylates the TSC2 tumor suppressor under conditions of energy
starvation, which serves to down-regulate mTOR signaling,53 and STK11 is required for this
repression of mTOR under low energy conditions. 54 In addition to inhibiting mTOR through
TSC2, AMPK also directly phosphorylates the mTOR binding partner RAPTOR which is
required for inhibition of mTORC1 and cell cycle arrest following energy stress. 55 These data
together suggest a model for STK11 as a "low-energy-checkpoint tumor suppressor" in that wild
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type STK11 acts as a sensor inducing AMPK signaling, which halts ATP-consuming processes
in conditions of low cellular energy. 49
STK11 is important in embryonic organogenesis in a tissue-dependent manner. Some
tissue specific examples of the effects of STK11 inhibition can be found in the pancreas where
this loss can lead to development of precancerous lesions in an AMPK-independent manner,
whereas inhibition of STK11 in the lung leads to a cell-autonomous branching defect, a
phenotype that can be rescued by an AMPK activator.56
For a representation of all of the downstream targets of STK11 see Figure 4.1.

STK11 AND TRANSCRIPTIONAL CONTROL

While regulation of the TSC2/mTOR pathway is clearly a major component of the
biology of STK11 mutations, STK11 also regulates the activity of a number of transcription
factors and transcriptional programs via poorly understood mechanisms. 57,58 The best
understood of these is the indirect control of CREB-regulated transcriptional cofactor (CRTC)
phosphorylation. CRCT proteins are excluded from the nucleus due to phosphorylation events
downstream of AMPK and AMPK-regulated salt-inducible kinases. In the absence of STK11,
CRTC1 accumulates in the nucleus due to lack of phosphorylation, binds to the CREB
transcription factor and activates transcription of CREB-regulated genes including LYPD3,
NR4A2,59 and NEDD9.60 Two papers have recently examined the transcriptional program
alterations associated with STK11 mutation in large lung adenocarcinoma databases61,62 and both
confirmed that CREB-regulated genes are dramatically affected by STK11 mutations. One of
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Figure 4.1 Downstream pathways controlled by STK11 and therapeutic targets. Inactive
STK11 is shown in red; active STK11 in green. Yellow 'P's represent phosphorylation events;
orange 'U's represent ubiquitination. Boxes in black represent downstream cellular processes;
boxes in red represent drugs used to inhibit or activate targets.
these two analyses62 also identified NRF2 activation and attenuation of the PI3K-AKT pathway
as elements of STK11 mutations, suggesting the potential for targeted therapies (discussed
below). Interestingly, the other paper demonstrated the STK11-CRTC1 circuit regulates COX-2
expression and its activation by glycosylation. 61 Furthermore, this paper used the C-MAP drug
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response database to demonstrate that the highest ranking drugs correlating positively with
STK11-mutated gene expression signature were activators of CRTC1 including forskolin and
numerous PGE-2 analogs. Finally, this work demonstrated that COX-2 inhibitors specifically
inhibited growth and motility in STK11-null cell lines and not in STK11-wild type cell lines,
suggesting potential clinical application (discussed below).

STK11 AND ADHESION

As a multifunctional tumor suppressor, STK11 has also been linked to not only intracellular processes, but also the extra-cellular process of adhesion. The N-terminal domain of
STK11 in particular has been found to be necessary for repressing the focal adhesion kinase
(FAK) and stabilizing focal adhesions.63 Loss of STK11 results in increased phosphorylation of
FAK and enhanced adhesion to fibronectin. 63 Adhesion of lung cancer cells to fibronectin has
previously been found to enhance tumorigenicity and confer cell adhesion mediated drugresistance.64 Specifically, fibronectin prevents apoptosis through integrin α5β1 mediated
activation of COX2 and inhibition of p21 gene expression, an effect not seen with other matrix
components such as collagen type I.65 Fibronectin has also been found to stimulate NSCLC cell
growth through activation of Atk, mTOR, and S6K with concurrent repression of STK11,
AMPK, and PTEN.66 This fibronectin-induced cascade can by blocked using an antibody
against integrin α5β1.66 Additionally, a novel tumor suppressor that binds to the cytoplasmic
domain of integrin α5, Nischarin, has also been found to directly interact with STK11. 67 Loss of
Nischarin and STK11 was found to increase migration and tumor growth through increased
phosphorylation of PAK1 and LIMK1, as well as increased Cyclin D1 levels. 67 Another STK11
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pathway found to negatively regulate cell adhesion involves the AMPK family member NUAK1
which is directly phosphorylated and activated by STK11. Inhibition of this STK11-NUAK1
pathway has been found to increase cell adhesion, and this pathway has been shown to be
activated under conditions of cell detachment. 68
Used as our model system for the study in Chapter 3, osteoblast differentiation was
found to correspond with decreased phosphorylation of AMPK, a phenotype that was found to be
inhibited by glucose restriction and metformin stimulation, 69 so there is likely a link between the
two pathways described. Another cross-over between the two major tumor suppressors
described in this dissertation is through the downstream regulation of the Rac1 pathway.
Treatment of endothelial cells with simvastatin resulted in increased phosphorylation of STK11
and AMPK with subsequent AMPK-mediated activation of Rac1. Through its downstream
pathway members STK11 has been shown to either activate or repress adhesion, adding to its
arsenal of tumor suppressive abilities.

THERPEUTIC IMPLICATIONS AND TARGETING OF STK11 MUTATIONS

At the molecular level, lung cancer is a complex and heterogeneous disease. Molecular
alterations in lung cancer occur at multiple levels (e.g., genetic, epigenetic, and protein
expression) and understanding the functional significance of these alterations can yield
improvements in diagnosis, prognosis, and treatment. 70 New technologies in the identification of
key and potentially targetable genetic alterations have resulted in a greater understanding of the
molecular underpinnings of lung cancer. Loss-of-function mutations, while more common, are
difficult to take advantage of therapeutically, so greater understanding of the multiple
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biochemical pathways and characterization of these molecular alterations is needed to develop
new therapeutic treatments and targeted precision medicine. STK11 in particular is an attractive
target because it is the major upstream activator of the energy-sensing kinase AMPK and has
been linked to a variety of important pathways in cancer. Restoring STK11 activity in mutant
tumors is predicted to both sensitize tumors to additional chemotherapies and to increase
susceptibility of cancer cells to cell death. Table 4.2 summarizes all of the clinical trials, preclinical studies, and basic science studies that have focused on targeting STK11 deficient tumors
using a variety of therapies.
A recent study sought to combine STK11 gene therapy with low-dose cisplatin-based
chemotherapy using cationic liposomes-mediated STK11 gene, which sensitized lung cancer
cells to cisplatin in vitro and in vivo, resulting in fewer lung metastatic nodules, and prolonged
lifespan.75 They believe this sensitization occurred through up-regulation of p53 and JNK and
down-regulation of mTOR and MMPs 2 and 9.
Apart from attempts to replace the down-regulated STK11 gene itself, strategies to target
downstream members of the STK11 pathway are in various stages of development and have
shown a range of efficacies. Some examples of this targeting strategy include taking advantage
of the fact that cells deficient in STK11 are known to be hypersensitive to apoptosis induced by
energy stress49 as a side effect of the dysregulated AMPK pathway. Using AICAR, an AMP
analog capable of stimulating AMPK, it was found that AICAR treatment prevented cell death
upon glucose depletion only in STK11 wild type cells79 and that multiple disparate types of
STK11-deficient cells are sensitized to cell death by AICAR. 49 Another means of targeting the
metabolic dysregulation caused by STK11 loss is use of the glucose analog, 2-deoxyglucose (2DG), which targets tumor cells due to their increased glucose uptake. In STK11-negative cells,
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Table 4.2: Therapies targeting the STK11 pathway by stage of development.
REGIMEN
DISEASE
CLINICAL TRIALS
Standard of
Colorectal
Care
cancer

N=

RESULTS

Evaluated STK11 SNP
rs741765

772
patients

Lee et al.71

PJS Patient
with
Pancreatic
Cancer
Lung
Adenocarcinoma

LOH analysis of 19p
locus using four
polymorphic markers

1
patient

Secondary Outcome;
Retrospective evaluation
of STK11 WT vs. Mut

Expect
60
patients

The STK11rs741765 SNP GG genotype is
prognostic for a worse DFS (p=0.030) and OS
(p=0.038).
Everolimus used to achieve a partial remission in
advanced pancreatic cancer in a PJS patient.
Progressive disease was noted after 9 mo. of
treatment.
Recruiting for Phase 2; Estimated completion
April 2015.

Advanced
Solid
Tumors
Stage IV
NS-NSCLC

Secondary Outcome;
Retrospective evaluation
of STK11 WT vs. Mut
Secondary Outcome;
Retrospective evaluation
of STK11 WT vs. Mut

Expect
64
patients
Expect
60
patients

Recruiting for Phase 1; Estimated completion
July 2017.

NCT02145559

Recruiting for Phase 2; Estimated completion
June 2018.

NCT02019979
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2-DG was found to activate apoptosis in response to energetic stress. 80 A third means of
exploiting the inability of STK11-mutant cells to appropriately respond to metabolic stress is the
use of therapeutic biguanides commonly used to treat diabetes, such as metformin and
phenformin.
Targeting mTOR has also been shown to be effective in STK11 mutant tumors. The
mTOR inhibitor everolimus was used to achieve a partial remission in a patient with advanced
pancreatic cancer induced by Peutz-Jeghers syndrome, although observable progressive disease
occurred after nine months of mTOR inhibition likely due to selective pressure for cancer cells
with alternative driver mutations, or a hyperactivation of an alternate pathway such as the AKT
pathway.72
STK11 has also been found to negatively regulate lysyl oxidase (LOX) through mTORHIF-1α signaling. LOX mediates lung cancer malignancy progression by triggering extracellular
matrix remodeling allowing for increased cell proliferation and invasion and could be a
therapeutic target for the treatment of STK11-deficient lung cancer. This is supported by the
work done by Gao et al. using the LOX pharmacological inhibitor, BAPN. 18
Another downstream target found to be upregulated in response to STK11-deficiency is
the COX-2 pathway (described above). A gene signature developed to determine STK11
mutational status was used to search the Connectivity-MAP drug response database and returned
results that were known or predicted activators of CRTC1, a transcription factor responsible for
regulation of COX-2.61 The COX-2 inhibitors NS-398 and Niflumic acid were shown to result in
growth and cell motility inhibition in STK11-null cell lines, but not their wild type
counterparts.61
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Previously, analysis of primary and metastatic de novo lung cancers with integrated
genomic and proteomic profiles led to the identification of gene and phosphoprotein signatures
associated with STK11 loss and progression to invasive and metastatic lung tumors. They found
that SRC is activatied in STK11-deficient primary and metastatic tumors and that combined
inhibition of SRC (using dasatinib), PI3K (using BEZ235), and MEK1/2 (using AZD6244)
resulted in synergistic tumor regression. 77
An additional method of STK11-mediated tumor suppression involves STK11 inhibition
of the Yes-associated protein (YAP), an oncogene more commonly associated with the Hippo
tumor suppressor pathway, which functions as a transcription factor responsible for promoting
expression of proliferative genes. STK11 suppresses YAP via indirect, non-canonical
regulation,82 preventing YAP from inducing EMT when constitutively active. 83 The structure of
YAP includes several protein domains that are promising drug targets. One such structure is the
N-terminal domain where YAP binds the TEAD transcription factor. This YAP-TEAD
interaction can be inhibited by verteporfin, which has been shown to prevent YAP-induced liver
overgrowth.84 Another YAP target is its WW domain which was identified in silico to be
targetable by digitoxin,85 and the endohedral metallofullerenol Gd@C82(OH)22,86 a molecule that
has previously been shown to have anti-neoplastic effects in tumor cells including the STK11
mutant A549 cell line.87 To our knowledge, no one has compared the efficacy of these therapies
in STK11-proficient and -deficient lung cancer cell lines.
Therapy decisions based solely on STK11 mutational status may not be enough, however.
Evidence in several studies has pointed to the idea that STK11/KRAS co-mutational patients may
represent a genetic and functionally distinct subset of NSCLC.73,78 STK11/KRAS mutant NSCLC
cell lines were found to be sensitive to the MEK inhibitor CI-1040 and the mTOR inhibitor
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rapamycin, whereas cell lines carrying single STK11 or KRAS mutations alone are not.78
Similarly, phenformin was found to selectively induce apoptosis in STK11-deficient NSCLC
cells, and in therapeutic trials using KRAS-dependent mouse models of NSCLC, tumors with
STK11/KRAS , but not those with KRAS/TP53 mutations, responded to phenformin as a single
agent leading to prolonged survival.76 An example where STK11/KRAS mutations represent a
resistant phenotype was in a "co-clinical" trial featuring genetically engineered mouse models
concurrently mirroring an ongoing human clinical trial in patients with KRAS-mutant lung cancer
where it was found that concomitant loss of either p53 or STK11 impaired the response of
KRAS-mutant tumors to docetaxel monotherapy. 73 Addition of the MEK inhibitor selumetinib
(AZD6244) provided substantial benefit for mice with KRAS mutations (92% overall response
rate) and KRAS/TP53 mutations (61% overall response rate), but mice with KRAS/STK11
mutations were more resistant (33% overall response rate). 73
Currently, a series of on-going clinical trials are recruiting patients to evaluate metformin
combined with either paclitaxel, carboplatin, or bevacizumab in lung adenocarcinoma (trial #
NCT01578551), metformin and sirolimus in advanced solid tumors (trial # NCT02145559), and
metformin combined with carbohydrate restriction and platinum-based chemotherapy in stage IV
non-squamous NSCLC (trial # NCT02019979). These trials will all evaluate STK11-mutational
status as a secondary outcome retrospectively.

CONCLUSION AND FUTURE DIRECTIONS FOR RESEARCH

Loss-of-function mutations, despite being common events in cancer, are largely ignored
when developing and selecting therapies. This is due to the fact that they are difficult to exploit
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as restoring function of a gene is not something that we are currently capable of. Despite this,
we have a responsibility to gain a complete understanding of the biology of these tumor
suppressors and the multitude of changes in key signaling pathways and downstream events
caused by their loss. With this information available, we have the best hope for developing the
most effective therapeutic regimens possible.
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CHAPTER FIVE:
A Gene Expression Signature Reflecting STK11 Mutation in Lung Adenocarcinoma XI

ABSTRACT

STK11 is a tumor-suppressor commonly mutated in lung adenocarcinoma (LuAd). There
are a number of agents that may selectively target the deregulated pathways in STK11 mutated
tumors, and thus, identifying the subset of adenocarcinomas that harbor these mutations could
have significant clinical benefit. In the current work, we have characterized a cohort of 442
adenocarcinoma patients with respect to STK11 mutation status and subset of this cohort using
immunochemistry, gene expression, and western blotting. We find that measuring STK11
mutation status is complicated by the fact that many STK11 mutations lead to expression of a
stable protein that is indistinguishable from wild type (WT) via immunohistochemistry. To
circumvent this, we used published cell line mutation and gene expression data to derive a
signature correlating with STK11 mutation status. This signature was validated in the cohort of
442 lung adenocarcinomas and strongly correlates with mutation status (ROC curve AUC =
85.29). These data suggest that STK11 mutation status may be best assessed by measuring the
downstream targets included in our signature.

XI

This chapter will be submitted for publication. See Appendix A for details.
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INTRODUCTION

STK11 is a serine/threonine kinase also known as liver kinase β1 (LKB1). It was first
discovered as the gene responsible for Peutz-Jeghers syndrome,1 a rare heritable disease
characterized by hamartomatous polyps of the gastrointestinal tract as well as hyper-pigmented
macules on the lips, gums, and inner lining of the mouth. STK11 has further been characterized
as a potent tumor suppressor, explaining the fact that Peutz-Jeghers patients have an
approximately 80% risk of developing cancer by age 70, 2 especially of gastrointestinal origin.
The STK11 gene is located on chromosome 19p13.3 and spans 10 exons, the 10th of
which is non-coding. The kinase domain of the 433 amino acid protein that it encodes spans
more than half the length of the protein encompassing amino acids 49-309. Mutations have been
found throughout the lengthy kinase domain with no obvious hotspots. The STK11 protein is
catalytically active as a heterotrimeric complex with the STE20-related adaptor protein α
(STRADα) and mouse protein-25 (MO25). STRADα binds STK11 in the nucleus and transports
it to the cytoplasm where it is active, 3 and it has been found that binding to STRADα increases
STK11's kinase activity more than 10-fold.4,5 In contrast, MO25 acts as a scaffold protein and
serves to stabilize the entire complex. Many mutations in STK11 have been found to interfere
with the capability to bind these partners, 6 rendering the expressed protein inactive.
While the diversity of mutations discovered in the STK11 gene is large, the range of
cancers that these mutations have been found in is comparatively small. The only cancer type
found to harbor a high percentage of STK11 mutations is non-small cell lung cancer (NSCLC).
The adenocarcinoma histological subtype of NSCLC in particular has a high frequency of STK11
mutations7-14 and is reported to be the third most commonly mutated gene in this cancer subtype
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following only KRAS and TP53,15 pointing to its importance as a driver mutation in
tumorigenesis. Mutations in STK11 have been found to commonly co-occur with KRAS
mutations, and to be mutually exclusive with EGFR mutations.11,15,16
The loss of STK11 can be particularly devastating to a cell as it plays a key role in
maintaining glucose homeostasis. STK11 is responsible for directly phosphorylating the AMPactivated kinase (AMPK) at T172, as well as other members of the AMPK family of kinases
under conditions of energy stress, 17,18 which in turn suppress mTOR activity through
phosphorylation of the tumor suppressor TSC2.19,20 Without STK11 acting as a glucose sensor,
cells are able to continue to grow unchecked in low glucose conditions such as those commonly
found in tumors. In addition to its role in metabolism, STK11 has also been linked to cell
polarity, epithelial-mesenchymal transition, cell cycle regulation, apoptosis, and autophagy. 10
Kinases, such as STK11, most commonly act as oncogenes, but as a tumor suppressor
STK11 drives tumor progression when it is lost, rendering it impossible to target directly.
Consequently, research is focused on targeting downstream targets of STK11. Therapies that
reactivate AMPK, such as metformin, phenformin, 21 and AICAR,18,22 and an AMP mimetic (2deoxyglucose)23 have been shown to render tumors more susceptible to chemotherapies.
Additionally, drugs that target the downstream proteins that are up-regulated by loss of STK11
such as mTOR inhibitors (e.g. rapamycin24 and everolimus25), cyclooxygenase 2 (COX-2)
inhibitors (e.g. NS-398 and Niflumic acid26), and lysyl oxidase inhibitors (e.g. BAPN14) have
shown efficacy in STK11 mutant cells as compared to their WT counterparts. Studies have also
been done to evaluate the differences in chemosensitivity between tumors that harbor
STK11/KRAS double mutations compared to STK11 alone.27,28
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Despite the growing body of evidence pointing to the efficacy of targeting this pathway
in lung adenocarcinoma, patients are not currently evaluated for STK11 mutational status as part
of standard of care treatment. Our work seeks to develop a clinically applicable test to determine
STK11 status by evaluating downstream markers. With this key piece of information, clinicians
will be able to design a more personalized therapy regimen for STK11 mutant lung
adenocarcinoma patients.

MATERIALS AND METHODS

Human subjects protection
This study includes data from 442 lung adenocarcinoma patients that consented to the
Moffitt Cancer Center's Total Cancer Care (TCCTM) protocol either at the Moffitt Cancer Center
(179 patients) or at one of 18 TCC affiliates (263 patients) between April 2006-August 2010.
This multi-institutional protocol has no exclusion or inclusion criteria and is open to all patients
willing to permit access to self-reported demographics, clinical data, medical records, and tissue
samples. These prospectively enrolled patients are followed for life. All work was approved by
the University of South Florida Institutional Review Board (Appendix B).

Western blotting
Frozen cell pellets were obtained from Fumi Kinose of the Moffitt SPORE in Lung
Cancer Cell Core facility. All lines were authenticated by genotyping and maintained free of
Mycoplasma. As previously described29, cell lysates were normalized for protein content (30 μg)
and separated using SDS-PAGE. Proteins were visualized using horseradish peroxidase
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conjugated secondary antibodies and enhanced chemiluminescence (ECL; Amersham
Biosciences, GE Life Sciences, Pittsburgh, PA, USA). Antibodies used include an STK11
mouse monoclonal antibody (sc-32245, Santa Cruz Biotechnology, Santa Cruz, CA, USA), a
MO25 rabbit polyclonal antibody (M7195, Sigma), a STRAD goat polyclonal antibody (sc55052, Santa Cruz Biotechnology), a threonine 172 phospho-AMPKα rabbit monoclonal
antibody (2535, Cell Signaling), an AMPKα1 rabbit polyclonal antibody (2795, Cell Signaling),
and a β-actin mouse monoclonal antibody (A5441, Sigma).

Immunohistochemistry
A tissue microarray (TMA) was constructed from available diagnostic paraffin blocks
from a subset of the Moffitt patients (N = 145) of the cohort described above. Slides from
potential donor blocks were stained with hematoxylin-eosin and examined by a board-certified
clinical pathologist. Appropriate blocks were released for study and representative tumor areas
(and a subset of normal tissue areas) marked. Donor tissue cores with a diameter of 0.6 mm were
punched and arrayed into a recipient paraffin block using a tissue arrayer (Beecher Instrument,
Silver Spring, MD, USA). The TMA included 145 cores from primary adenocarcinomas, 58
cores of adjacent normal lung tissue, 14 cores from non-lung tissue controls (normal and cancer)
and 10 samples of lung cancer cell lines of known STK11 status (which were used to
demonstrate the specificity of STK11 staining).
TMA slides were cut into 4 µM sections and stained with a mouse anti-STK11
monoclonal antibody (sc-32245, Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a 1:100
dilution (staining details are available upon request). The stained TMA was reviewed by a boardcertified clinical pathologist blind to the molecular data. Normal tissue cores were examined to
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determine staining criterion. The staining of tumor tissue was scored as either negative or
positive with positive values ranging from +2 to +4.
A histology slide from a tissue micro array stained for STK11 (sc-32245, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) was scanned using the Aperio™ (Vista, CA, USA)
ScanScope XT with a 200x/0.8NA objective lens at a rate of 7 min per slide via Basler tri-lineararray detection. Each core was then segmented using the TMA block software associated with
Spectrum to be analyzed individually. Image analysis for 227 stained cores was performed using
an Aperio Positive Pixel Count® v9.0 algorithm with the following thresholds: [Hue Value =.1;
Hue Width =.5; Color Saturation Threshold =0.04; IWP(High) = 220; Iwp(Low)=Ip(High) =
175; Ip(low) =Isp(High) =100 Isp(Low) =0] to segment positive staining of various intensities.
The algorithm was applied to the entire digital core image to determine the percentage of
positive biomarker staining by applicable area.

Statistical analysis
The mutational data, IHC data, clinical information, and vital status data were merged
into a single file for subsequent statistical analyses using Stata/MP 12.1 (StataCorp LP, College
Station, TX, USA). Pearson's chi-squared test was used to test for differences in the distributions
of mutational status by study population characteristics. The Student’s t-test was used to test for
differences in the mean IHC values by mutational status. Survival analyses were performed
using Cox proportional hazard regression, Kaplan-Meier survival curves, and the log-rank test.
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Plasmid vectors
The pcDNA3-FLAG-LKB1 vector was purchased from Addgene (Plasmid #8590;
Addgene, Cambridge, MA, USA). The STK11 gene insert was amplified from this plasmid using
the T7 promoter and custom primer (5'-ATACTCGAGCTGCTGCTTGCAGGC-3'), excised
using EcoRI and XhoI restriction enzymes, and cloned into those sites of the pNTAPb vector
(Agilent Technologies, Santa Clara, CA, USA). STK11 variants were generated by PCR using
the following primers: D194Y forward (5'-ACCCTCAAAATCTCCTACCTGGGCGTGGC-3'),
D194Y reverse (5'-GCCACGCCCAGGTAGGAGATTTTGAGGGT-3'), P281fs*6 forward (5'GACTGTGGCCCCCGCTCTCTGACCTG-3'), P281fs*6 reverse (5'CAGGTCAGAGAGCGGGGGCCACAGTC-3'), F354L forward (5'AGGACGAGGACCTCTTGGACATCGAGGATG-3'), F354L reverse (5'CATCCTCGATGTCCAAGAGGTCCTCGTCCT-3').

STK11 gene expression
Patients consented under the TCCTM protocol described above were profiled for
expression of ~60,000 distinct transcripts using a custom Affymetrix GeneChip. Tissues were
processed and RNA quality assessed according to the TCCTM protocol. The patient cohort was
then de-identified, GeneChip data extracted, analyzed for hybridization quality, and processed
using Robust Multi-Array Analysis, a model-based method of calculating expression signal.
Microarray expression analyses were performed with CRAN, R Bioconductor using the LIMMA
package. The gene expression data were normalized using a pin-based Lowess-fit normalization
algorithm. Probesets were merged on gene symbols using a signal-to-noise-based weighted
approach and features with more than 20% missing values were removed.
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Transfection and immunoprecipitation
Cells were cultured in RMPI supplemented with 10% fetal bovine serum plus 1%
penicillin/streptomycin. H1299 cells were cultured in 150 mm plates to approximately 70-80%
confluency. They were then transfected with 13 μg vector (pNTAPb), Mef2a control, or one of
the STK11 variants, D194Y, P281fs*6, or F354L, plus 41 μg ssDNA mixed with 130 μL
Lipofectamine-2000 in a total of 30 mL of serum-free media. This mixture was left on the cells
for 4 hours, then changed to complete media. After 48 hours, cells were harvested and
immunoprecipitated using streptavidin beads following the manufacturer's protocol (InterPlay
Mammalian TAP System, Agilent Technologies, Santa Clara, CA, USA) stopping after the
streptavidin elution with the exception that NETN (0.5% v/v Nonidet P-40, 20 mM Tris pH 8.0,
50 mM NaCl, 50 mM NaF, 100 μM Na3NO4, 1 mM DTT, and 50μg/mL PMSF) was used in
place of both the manufactuer's Lysis buffer and Streptavidin binding buffer. The proteins were
eluted in 30 μL 2X Laemmli buffer and the entire elution was run on the SDS-PAGE gel for
western blotting.
A549 cells were cultured as above in 100 mm plates to 70-80% confluency. They were
then transfected with 1 μg vector (pNTAPb), WT STK11, or one of the STK11 variants, D194Y
or F354L, additional plates received co-tranfections of WT STK11 with each of the STK11
variants at ratios of 1 μg variant plus 1 μg WT, 1 μg variant plus 5 μg WT, or 1 μg variant plus
10 μg variant. All transfections were brought up to a total of 11 μg DNA using ssDNA mixed
with 60 μL Lipofectamine-2000 in a total of 15 mL of serum-free media. This mixture was left
on the cells for 4 hours, then changed to complete media. After 48 hours, cells were harvested
and western blotted as described above.
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Generation of STK11 mutation signature
Cell line gene expression and metadata was obtained from ArrayExpress30 accession EMTAB-783, supplemented with additional data from the Sanger Cell Line Project
(http://www.broadinstitute.org/cgi-bin/cancer/datasets.cgi). CEL files were normalized using
IRON31 against the median sample. Histology and site of origin was conformed, and several
mis-annotated cell lines, identified as outliers through principle component analysis (PCA), were
corrected for histology and site of origin where supported by literature (A4-Fuk, MDA-MB-435,
NCI-H1155, NCI-H1299, NCI-H1770, NCI-H810, SK-NEP-1). Large differences in gene
expression were observed due to batch effect (Affy_batch in the Sanger/Broad metadata), and
corrected for with COMBAT32 using a conformed combination of site of origin and histology as
the covariate.
STK11 mutational status for NSCLC cell lines was curated from the literature (Luc
Girard, personal communication) and confirmed in select cases by western blot. Preliminary
partial least squares discriminant analysis (PLS-DA), trained to separate mutant vs. WT,
indicated that four WT cell lines (H292, H2170, H2342, EKVX) exhibited mutant-like gene
expression patterns. These four outlier cell lines were omitted from further signature generation
analysis. An STK11 mutation signature was generated by comparing mutant vs. WT groups
using the following criteria for differential expression: at least three samples must have a log2
intensity greater than 5, |fold-change| ≥ 2, and p-values from both T-test and Mann-Whitney Utest < 0.01. The signature was further reduced by keeping only those probesets most associated
with the first PCA component.
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RESULTS

Expression of STK11 protein in lung adenocarcinoma
Forty-two cell lines with known STK11 mutational status were examined via western blot
for STK11 protein expression (Figure 5.1A). In all STK11 mutant cell lines, protein expression
was absent. In STK11 WT cell lines the protein generally appeared as a single band, however
some cell lines blotted as a doublet or triplet, although always expressing the band for full-length
protein of approximately 52 kD. The exceptions were H2170, which only blotted for lower
weight bands, and the EKVX and Calu-3 cell lines, which expressed extremely faint bands of the
expected size.
In work described elsewhere, we examined a cohort of 442 adenocarcinoma patients for
mutations in KRAS, EGFR, TP53, and STK11. This analysis revealed that a high percentage of
LuAd possessed mutations and copy number variations in the STK11 gene. Many of the
mutations identified in the previous study were of unknown significance, and thus, we sought to
determine whether LuAd samples harboring these STK11 mutations would express STK11
protein. In contrast to the cell lines, blotting patient samples for STK11 yielded a wide range of
protein expression for both WT and mutant tumors (Figure 5.1B). The presence of WT normal
tissue contaminating the tumor sample may account for some mutant tumors that express high
levels of protein, but assigning STK11 mutational status by the presence or absence of a western
blot band would be highly inaccurate.
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Figure 5.1: STK11 protein expression in cell lines and lung adenocarcinoma tumor
samples. (A) Cell lines of known STK11 mutational status (denoted in parentheses) and (B)
patients with tumors sequenced for STK11 mutational status (listed above each lane) were blotted
for STK11 (sc-32245, Santa Cruz Biotechnology) and β-actin (A5441; Sigma). Repeated cell
lines were obtained from different laboratory sources.

IHC staining
STK11 staining in normal lung epithelial tissue was generally light, cytoplasmic and
diffuse and was set to a +4 value. The staining of tumor tissue ranged from 0 to 4+ (Figure
5.2A). Under the staining conditions used, infiltrating lymphocytes stained a very dark brown,
but were ignored when assigning a staining score. Upon measuring staining using automated
software, STK11 mutant tumors were found to have statistically significantly lower levels of
protein compared to the WT tumors (P=0.001) (Figure 5.2B). However, despite this trend,
similar to the western blotting results, both STK11 WT and mutant tumors exhibited a wide range
of staining.
When we dichotomized the IHC data at the overall median value, we found that tumors
with low STK11 protein levels had improved survival compared to those with high STK11
protein levels (Figure 5.2C), however this difference was not statistically significant (P = 0.142).
The trend remained when we restricted this analysis to early stage tumors (data not shown), but
the data were not statistically significant (P = 0.183).

Characterization of three recurring STK11 variants
Three STK11 patient variants were chosen from the list of mutations that were found to
reoccur in our previous work and previously published studies from other groups. These
variants, D194Y, P281fs*6, and F354L, were examined for mRNA expression levels of the
STK11 gene (Figure 5.3A). Due to our small sample size for each mutation, no statistically
significant trends were found, but the D194Y mutant had the highest STK11 expression, almost
equivalent to the average expression of WT samples. The F354L polymorphism, which has
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Figure 5.2: STK11 IHC and survival probability. (A) IHC was run on a panel of 145 lung
adenocarcinoma tumors of known STK11 mutational status; representative cores were chosen for
each staining level for both STK11 WT (on top) and STK11 mutant tumors (on bottom, with
mutation listed under picture). For the 4+ staining mutant sample, the DNA mutation occurred
two base pairs into the intron splice site with unknown effect on the resulting protein
(Unknown). (B) The percent positive pixels staining for STK11 for each core was determined
using the Aperio Positive Pixel Count® algorithm, stratified by mutational status of the core, and
separated into quartiles. (C) Survival probability for both STK11 mutant and WT tumors was
determined using a Kaplan Meier curve. No significant difference was noted.
108

previously been found in Asian populations at approximately 10% frequency,33 has been called a
polymorphism in lung cancer, having no effect on STK11 catalytic activity. We decided to
explore it further, however, because it has also been reported to affect cell polarity through an
AMPK-dependent mechanism.34 This F354L variant expressed STK11 at levels just greater than
the average mutant sample still falling within the range of the second quartile of WT STK11
expression. The P281fs*6 mutation resulted in the lowest STK11 expression of the three variants
examined, with expression levels just above the first quartile of all STK11 mutant samples.
We next sought to determine if the three variants could bind the other members of the
catalytically active STK11 trimeric complex, MO25 and STRAD. This was done by transfecting
WT STK11 as well as each of the three variants into H1299 cells which contain an intact STK11
pathway. The exogenous STK11 was immunoprecipitated using streptavidin beads and blotted
for its binding partners. The WT STK11, as well as the D194Y and F354L variants were able to
bind MO25 and STRAD (Figure 5.3B). The P281fs*6 mutant, however, showed no binding to
either MO25 or STRAD, and was thus dropped from further characterization as STK11 is
catalytically inactive without the other members of the complex.
Finally, we examined the remaining two variants for dominant negative activity by
transfecting the variant alone, and variant plus WT in 1:1, 1:5, and 1:10 ratios, into A549 cells
which lack endogenous STK11 and looking for downstream phosphorylation of AMPK. The
D194Y mutant was able to suppress activation of AMPK by the WT STK11 at all ratios
examined, keeping AMPK phosphorylation levels close to ambient background, as measured
when transfecting in the empty vector alone (Figure 5.3C) marking it as a dominant negative
form of the STK11 protein. This D194Y mutation has previously been noted in Peutz-Jeghers
syndrome, NSCLC, and has been found to be a residue involved in Mg 2+ binding and catalysis,
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Figure 5.3: Characterization of three recurring STK11 variants. (A) The panel of 442 lung
adenocarcinomas were evaluated via microarray for gene expression of STK11, stratified by
mutational status, and separated into quartiles. STK11 expression for the three variants that were
chosen, D194Y (N=3), P281fs*6 (N=4), and F354L (N=4), were averaged and plotted against
the STK11 mutant quartiles. (B) Empty vector, a vector control, WT STK11, and each of the
three variants were transfected into H1299 cells, immunoprecipitated using streptavidin beads,
and blotted for binding to MO25 (M7195, Sigma), and STRAD (sc-5502, Santa Cruz). (C)
Empty vector, WT STK11, and each of the three variants alone, and variant plus WT in 1:1
(denoted with +), 1:5 (denoted with ++), and 1:10 (denoted with +++) ratios, were transfected
into A549 cells and blotted for AMPK phosphorylated at T172 (p-AMPK; 2535, Cell Signaling),
total AMPK (AMPKα1; 2795, Cell Signaling) and β-actin (A5441; Sigma).
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so despite being expressed, the lack of downstream activation of the pathway correlates to the
importance of this residue.35-37 Conversely, the F354L variant phosphorylated AMPK in the
presence, or absence, of WT protein, and is likely a polymophism that does not have any real
effect on the protein's catalytic activity.

An STK11 gene expression signature derived from a panel of cell lines of known STK11
mutational status
Forty-eight cell lines (Table A1) with defined STK11 status and gene expression data
from the Connectivity Map (CMAP) of the Broad Institute (http://www.broadinstitute.org/) were
used to define a gene signature correlating with STK11 mutation status. The genes used to make
the signature are listed in Table A2. Figure 5.4A shows the first and second principle
components of the signature for all cell lines. The first principle component separates the cell
lines into WT and mutant, except for five lines indicated in yellow (H292, H2170, H2342, and
two sources of EKVX). In the Western blot analysis of these cell lines (Figure 5.1A), H292
appears as a triplet, H2170 is missing the wild type band but has three lower molecular weight
bands, H2342 has a band at the expected wild type size, and EKVX has a faint band of the
expected wild type size. All of these lines were excluded from further analysis. NR4A2 is the
strongest gene in the signature and has previously been found to be downstream of STK11 38,39
with potential to be used as a marker of STK11 mutation.

The STK11 gene signature can be used to classify human tumors
We next assessed the STK11 gene signature using the panel of 442 lung adenocarcinoma
for which the mutation status and copy number (data not shown) of STK11 was determined.
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Figure 5.4: STK11 gene expression signature. (A) First principal component analysis of an
STK11 gene expression signature was developed in cell lines; units are arbitrary. (B) First
principal component analysis of this gene expression signature validation in the cohort of 442
patients; units are arbitrary. (C) The performance of the STK11 gene signature, developed in cell
lines was tested using a receiver operating characteristic (ROC) curve to determine how well it
correlated with known STK11 mutational status samples in the 442 patient cohort.
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Figure 5.4B demonstrates that the signature derived in cell lines is also present in in vivo tumors.
There are exceptions on both sides. Our gene expression signature was also found to highly
correlate with STK11 mutational status as seen in the ROC curve (AUC = 85.29) (Figure 5.4C).

CONCLUSIONS

We have examined STK11 DNA mutational status and the resulting levels of both STK11
mRNA and protein and found that while a mutation in the DNA sequence results in an inactive
protein, it does not necessarily abrogate expression of either mRNA or protein. Conversely, WT
STK11 tumors have been shown to have a wide range of expression of both STK11 mRNA and
protein. While DNA sequencing is a viable option to determine a patient's STK11 mutational
status, it is a cumbersome process involving the sequencing of nine individual exons. The
majority of mutations revealed through sequencing have not been characterized for downstream
activity, so even after sequencing it is unclear whether the STK11 downstream pathway has
indeed been inactivated. In order to solve this problem, we have developed an STK11 gene
expression signature comprising genes both related to and downstream of STK11 and the STK11
pathway. This signature can separate both STK11 WT and mutant cell lines and patient samples.
With the resulting STK11 mutational status in hand, a clinician will eventually be able to
offer patients a more personalized treatment regimen of one of the many drugs in development to
target the altered STK11 pathway. In our own work we have found that our STK11 signature
correlates with drug sensitivity to COX-2 inhibitors (data not shown) and have published a study
looking at the effects of these COX-2 inhibitors in both STK11 WT and mutant cell lines.26
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With the American Cancer Society estimating over 224,000 new incidences of lung
cancer in the U.S. in 2014 (Cancer Facts and Figures), and approximately 35-40% of these lung
cancers being classified as adenocarcinoma, there is a huge demand for a test like ours and we
look forward to helping these patients receive the most efficacious treatment possible.
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CHAPTER SIX:
Conclusions and Future Directions for Research

TARGETING TUMOR SUPPRESSORS

Current strategies to treat cancer rely heavily on reducing the activity of overactive
oncogenes, however this approach largely ignores tumor suppressors, as restoring function of
these sentinel proteins is a more difficult task. There are several strategies that seek to restore
the activity of tumor suppressors, most commonly through targeting downstream pathway
members which are amplified upon loss of the tumor suppressor. Other targeting strategies
include directly restoring normal gene expression through gene therapy. This involves
packaging wild type tumor suppressor DNA in viral hosts and using them to infect tumor tissues,
or less commonly by using either DNA plasmids directly, or packaging these plasmids in
liposomes or polymers.1 For tumor suppressors that are being suppressed by DNA methylation
or histone deacetylation, activity may be restored through the use of DNA methyltransferase
inhibitors (e.g. Decitabine) or histone deacetylase inhibitors (e.g. Vorinostat and Romideosin). It
has also been suggested that bypassing restoration of tumor suppressor function may be a viable
option through the use of microRNAs. Similar to proteins with oncogenic or tumor suppressive
functions, specific microRNAs may fulfill these same roles and restoring faulty microRNAs may
be an easier task with more far-reaching effects as individual microRNAs have been shown to
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regulate hundreds of genes. A riskier strategy involves actually targeting normally functioning
tumor suppressors that are redundant activators of pathways no longer activated by the tumor
suppressor lost in cancer cells. The idea behind this strategy is that targeting a redundant protein
in healthy tissues will be compensated for by the normally functioning tumor suppressor. In
tumor tissues, however, where the tumor suppressor is already lost, targeting the redundant
protein will abrogate all activation of the essential pathway leading to cancer cell death. Proofof-concept studies using this strategy targeted the genes ENO1 and ENO2 in glioblastoma.2
There is still a lot of work that needs to be done to develop strategies to restore activity of each
of the major tumor suppressor, but the concepts described above may prove effective in the
future.
The two major tumor suppressors discussed in this dissertation can currently be targeted
in cancer using several of the strategies mentioned above. Specifically, the pRb pathway can be
targeted by inhibiting downstream pathway members that are up-regulated upon loss of pRb
using CDK inhibitors and E2F inhibitors. Restoration of pRb activity is also being attempted by
re-expressing the CDKN family member, p16, which is itself a tumor suppressor, using
adenovirus-mediated gene therapy.3 Similarly, adenovirus-mediated gene therapy has been used
to try to restore the STK11 gene, while the downstream pathway is being targeted by inhibiting
proteins that are up-regulated upon loss of STK11 using mTOR inhibitors, COX-2 inhibitors,
and LOX inhibitors. Reactivation of the downstream pathway is being achieved using AMPK
activators such as metformin, phenformin, and AICAR. Understanding the molecular biology of
these two major tumor suppressors is vital in our quest to develop additional strategies to
specifically restore the function of these critical proteins.
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CONCLUSIONS FROM THE WORK PRESENTED IN THIS DISSERTATION

Chapters 2 and 3 explored the major tumor suppressor, pRb. This protein, which is lost
in the majority of human cancers has been widely characterized as a cell cycle suppressor, but
newly emerging work is also linking it to the process of cell-to-cell and cell-to-extracellular
matrix adhesion. The status of current work outlining the mechanisms and pathways by which
pRb controls these adhesive properties is leading toward a greater understanding of this protein
and paving the way for future means of exploiting its loss therapeutically. Specifically, pRb was
found to up-regulate expression of the adhesion protein, integrin α10. In addition to changes in
this integrin subunit, three others, integrins α7, α8, and β4 were also found to undergo changes in
expression in tumor tissue compared to normal tissue in multiple common solid tumor types.
Chapter 4 and 5 discussed the major tumor suppressor STK11 with a focus on its
molecular biology and therapeutic implications. Currently there are no approved therapies
specifically for patients with STK11 loss-of-function mutations, however a variety of strategies
are being explored at the basic science, pre-clinical, and clinical trial levels. These therapies
seek to restore normal pathway activity in patients affected by loss-of-function STK11 mutations.
Once therapies are approved, the next question will be how to identify patients that will benefit
from these therapies, as patients are not currently clinically evaluated for their STK11 mutational
status. Our work has identified a gene signature made up of downstream pathway members and
other genes affected by STK11 loss-of-function mutations. This signature can identify patients
with an aberrant STK11 pathway with the hope that these patients will soon be eligible to receive
therapies specifically targeting their personal mutational spectrum.
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FUTURE WORK ON INTEGRINS

The majority of our experimental work on integrins was focused on the transcriptional
control of integrin α10 with bioinformatic work that led to the identification of an 'integrin
switch' in multiple solid tumors. Further work would be necessary to fully characterize the four
integrins involved and confirm the bioinformatically identified 'switch.' Real-time PCR could be
used to quantify differences in transcriptional levels of integrin mRNA, while western blotting or
immunofluorecence could be used to visualize changes in the levels of these proteins in the
predicted solid tumor types. Changes in the mRNA or protein levels of these four integrins
could be further analyzed for their expected correlation to the proclivity of tumors to metastasize
with high levels of the three protective integrins, α7, α8, and α10 indicating a good prognosis,
and high levels of the detrimental integrin, β4, indicating a poor prognosis. This four integrin
signature could potentially be developed into a prognostic patient biomarker test. Increased
levels of integrin β4 could also be targeted therapeutically as the extracellular domains of
integrins could be ideal substrates for small molecule inhibitors, targeted antibodies, or bindingdomain peptide mimetics.
Another potential future direction for the integrin project involves the continued
elucidation of pRb's control of several other adhesion proteins. Our preliminary work identified
multiple integrins and cadherins that appeared to be regulated by pRb including upregulation of
cadherins 1, 11, and 26 as well as integrins α1, α8, and β3 and downregulation of cadherins 2 and
6, as well as integrins α6, β7, and βL1, relationships all confirmed by real-time PCR in pRbproficient and -deficient SAOS-2 osteosarcoma cells. These relationships could all be further
explored for the mechanism linking them to pRb.
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Ultimately, our work serves to strengthen the link between pRb and adhesion. While
there are drugs that target each of these pathways individually, developing therapeutic regimens
that combine these drugs, or eventually developing targeted therapies to restore adhesion
dysregulated by the loss of pRb may be an extremely beneficial strategy for treating the greater
than 50% of human tumors that are characterized by loss of pRb.

FUTURE WORK ON STK11

Additional work on STK11 is currently underway with our gene expression signature
being transformed into codesets compatible with the Nanostring platform. This platform is an
amplification-free method for detecting small amounts of mRNA from patient samples through
hybridization to fluorescently bar-coded probes for predetermined target genes. These results
will be compared with our previous microarray-based signature to narrow down our gene list to
those that are similarly modified on both platforms helping to create the smallest, most robust
signature possible. This newly refined signature will also be tested in outside datasets
independent of the 442 patients from the SPORE cohort. These datasets, including the TCGA,
may help refine the gene list to narrow it down to the smallest number of maximally informative
genes. With the final gene list defined, the ultimate goal for this signature is to develop it into a
patient diagnostic test used to clinically identify the mutational status of STK11 in order for
patients to receive treatment specific to their unique mutational landscape. With multiple clinical
trials currently underway investigating the response of STK11 mutant and wild type patients to a
variety of therapies, it is our hope that evaluating the status of this gene will be informative for
future standard of care therapy options.
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This gene expression signature was also tested against CMAP drug-response signatures
resulting in a series of hits. These drugs were largely related to prostaglandins and the COX-2
pathway. Some initial work was done on testing a few of these drugs in STK11-proficient and deficient cell lines. Follow-up studies on more of the drugs, including the subset that are not
COX-2 inhibitors, may yield viable treatment options not yet explored for STK11 mutant
patients. Lung adenocarcinoma is a very deadly disease and currently no targeted therapies are
available for patients with STK11 mutations. Our work will continue to focus on identifying new
therapeutic strategies and the patients that will benefit most from them.

THE FUTURE OF CANCER TREATMENT

In the words of Hippocrates, "It is more important to know what sort of person has a
disease than to know what sort of disease a person has." While this concept has been around for
several millennia, it is truly the future of cancer treatment. With the widespread use of
oncogenomics to analyze each patient's individual mutation spectrum and develop a unique
treatment regimen, 'personalized medicine' is truly becoming a reality. With a strong foundation
of basic science being translated into the clinic, it is our hope that each piece of information we
uncover about the inner workings of these devastating cancers will result in more effective
treatments in the future.
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It was the determination of the IRB that your study qualified for expedited review which includes
activities that (1) present no more than minimal risk to human subjects, and (2) involve only procedures
listed in one or more of the categories outlined below. The IRB may review research through the
expedited review procedure authorized by 45CFR46.110 and 21 CFR 56.110. The research proposed in
this study is categorized under the following expedited review category:
(5) Research involving materials (data, documents, records, or specimens) that have been collected, or
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will be collected solely for nonresearch purposes (such as medical treatment or diagnosis).
Your study qualifies for a waiver of the requirements for the documentation of informed consent as
outlined in the federal regulations at 45CFR46.116 (d) which states that an IRB may approve a consent
procedure which does not include, or which alters, some or all of the elements of informed consent, or
waive the requirements to obtain informed consent provided the IRB finds and documents that (1) the
research involves no more than minimal risk to the subjects; (2) the waiver or alteration will not adversely
affect the rights and welfare of the subjects; (3) the research could not practicably be carried out without
the waiver or alteration; and (4) whenever appropriate, the subjects will be provided with additional
pertinent information after participation.
Your study qualifies for a waiver of the requirement for signed authorization as outlined in the HIPAA
Privacy Rule regulations at 45 CFR 164.512(i) which states that an IRB may approve a waiver or
alteration of the authorization requirement provided that the following criteria are met (1) the PHI use or
disclosure involves no more than a minimal risk to the privacy of individuals; (2) the research could not
practicably be conducted without the requested waiver or alteration; and (3) the research could not
practicably be conducted without access to and use of the PHI.Waiver of HIPAA Authorization has been
approved for you to conduct a secondary analysis of identifiable data that are collected under Moffitt
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with IRB policies and procedures and as approved by the IRB. Any changes to the approved research
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We appreciate your dedication to the ethical conduct of human subject research at the University of South
Florida and your continued commitment to human research protections. If you have any questions
regarding this matter, please call 813-974-9343.
Sincerely,

USF Institutional Review Board
Cc: Vicki Stecher, MA, USF IRB Professional Staff
Diane Martinez, Manager, Moffitt
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APPENDIX C: Cell Lines Used to Derive the STK11 Signature
Table A1: Cell lines used to derive the STK11 signature
Cell Line
H1437**
H2126
H1993
H1395*
H1355
H460
A549
H1573
H2030
EKVX*
H1755
H292
H23
H1666
H838
A427
H2342
H157
H2170
H520
H1563
H2405
H1650
Calu-3
H441
H2009
H1651
H522
H596
H661
H1703
H1793
H1693
H358
H1792
H2228
H1838
Calu-6
H650
H2087
H1975
Calu-1
H2347
H2291
HOP-92
SK-LU-1
HOP-62
H226

NSCLC Subtype
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Large Cell
Carcinoma, unspecified
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Mucoepidermoid
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Carcinoma, unspecified
Adenocarcinoma
Squamous Cell Carcinoma
Squamous Cell Carcinoma
Squamous Cell Carcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Large Cell Carcinoma
Squamous Cell Carcinoma
Adenocarcinoma
Adenocarcinoma
Bronchioalveolar
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Bronchioalveolar
Adenocarcinoma
Adenocarcinoma
Epidermoid carcinoma
Adenocarcinoma
Adenocarcinoma
Large Cell Carcinoma
Adenocarcinoma
Adenocarcinoma
Squamous Cell Carcinoma

STK11 Status
E98-G155del
Y156-G268del
E199*
E57Kfs*7
K48fs*3
Q37*
Q37*
S216F
E317*
WT
P281fs*6
WT
W332*
A200fs*87
T212fs*75
Large N-term deletion
WT
E98-G155del
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT

NSCLC subtype from ATCC; STK11 status from the Connectivity Map (CMAP) of the Broad
Institute (http://www.broadinstitute.org/). Cell lines are listed in the ranked order of their first
principle component with most 'mutant-like' listed first and most 'WT-like' listed last. Single
asterisks indicate cell lines that had two subtypes that were used to derive the signature. Double
asterisks indicate cell line that had three subtypes that were used to derive the signature.
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APPENDIX D: Genes in the STK11 Signature
Table A2: Genes in the STK11 signature
ABCA1
ADRB2
ALDH3B1
APBB2
APOBEC3G
ARHGEF3
ATF7IP
AVPI1
BCAT1*
C21orf96
CASP9
CDKN1C
CEP170
CFI
CLIC2
CLIP4
CPS1*
CSGALNACT1
CTSB
CYP1B1*
DENND4B
DLG1
DPM3
DPYD
DPYSL3
EDNRA
EFNB3
EPB41L2
EPHB2*
FGA*
FGB
FGG
FLJ20935 fis, clone ADSE01534
FOXN3
Glutaminase isoform C
GRAMD1B
GRK5
GUCY1B3
HAL*
HEG1
HERC6
HGD
IFI27
IFI44
IFI44L
IFIT1
IGF2BP2
KCTD14 NDUFC2-KCTD14
KIAA1598
LGSN

LHFP
LYST*
MALT1
MAP7*
MECOM
MERTK
MFGE8
MUC5B
MX2
MYLK
NPC2
NR4A1
NR4A2*
NR4A3
PDE4B*
PDE4D*
PDLIM4
PDP1
PELI1
PLSCR1
PRKAA2
PSIP1
PTGES*
PTP4A1*
SEC14L1*
SEC14L1 LOC729799
SETD6
SH2B3
SHANK2*
SIK1
SLFN12
SLIT2
SMAD2*
SPATS2L
SPDEF
STAC
TACC2*
TBC1D30
TFF1
TRIM2
TRIO*
TYMP*
UBE2L6
ZCCHC24
ZFP36L1*
ZNF177 ZNF559-ZNF177
ZNF415
ZNF43*
ZNF85
ZNF93*

Genes are listed alphabetically. Asterisks indicate that multiple probesets were used for that
gene.
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